<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:56.4pt;left:116.6pt;line-height:9.4pt"><span style="font-family:Times New Roman,serif;font-size:9.4pt;color:#000101">International Journal of</span><span style="font-family:Times New Roman,serif;font-size:8.8pt;color:#612d64"> </span><sup><b><i><span style="font-family:Times New Roman,serif;font-size:8.8pt;color:#4f4424"> </span></i></b></sup></p>
<p style="top:67.9pt;left:116.6pt;line-height:11.3pt"><b><i><span style="font-family:Times New Roman,serif;font-size:11.3pt;color:#3a1b3c">Molecular Sciences</span></i></b></p>
<img style="position:absolute;transform:matrix(.15624357,0,-0,.1565575,485.88453,-25.217606)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.15624357,0,-0,.1565575,485.88453,-25.217606)" src="data:image/png;base64,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==">
<img style="position:absolute;transform:matrix(.15624357,0,-0,.1565575,485.88453,-25.217606)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.15624357,0,-0,.1565575,485.88453,-25.217606)" src="data:image/png;base64,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">
<p style="top:100.5pt;left:76.2pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Review</span></i></p>
<p style="top:113.4pt;left:76.5pt;line-height:17.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:17.9pt">Ibrutinib in Gynecological Malignancies and Breast</span></b></p>
<p style="top:133.6pt;left:76.5pt;line-height:17.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:17.9pt">Cancer: A Systematic Review</span></b></p>
<p style="top:169.7pt;left:76.3pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Julian Matthias Metzler *</span></b></p>
<p style="top:169.7pt;left:200.8pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">, Laurin Burla, Daniel Fink and Patrick Imesch</span></b></p>
<p style="top:187.7pt;left:82.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Department of Gynecology, University Hospital Zurich, 8091 Zurich, Switzerland; laurin.burla@usz.ch (L.B.);</span></p>
<p style="top:199.8pt;left:82.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">daniel.&#xfb01;nk@usz.ch (D.F.); patrick.imesch@usz.ch (P.I.)</span></p>
<p style="top:211.9pt;left:81.4pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">*</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Correspondence: Julian.Metzler@usz.ch</span></p>
<p style="top:237.9pt;left:82.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Received: 13 May 2020; Accepted: 7 June 2020; Published: 10 June 2020</span></p>
<p style="top:229.9pt;left:487.1pt;line-height:7.9pt"><span style="font-family:SourceSansRoman,serif;font-size:7.9pt">&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;</span><span style="font-family:SourceSansRoman.613wght,serif;font-size:7.0pt">&#xfffd;</span></p>
<p style="top:237.0pt;left:487.1pt;line-height:7.9pt"><b><span style="font-family:SourceSansRoman,serif;font-size:7.9pt">&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;</span></b></p>
<p style="top:260.3pt;left:81.8pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Abstract:</span></b><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> Ibrutinib is an orally available, small-molecule tyrosine kinase inhibitor. Its main purpose</span></p>
<p style="top:273.8pt;left:82.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">is to inhibit Bruton&#x2019;s tyrosine kinase (BTK), an enzyme that is crucial in B cell development.</span></p>
<p style="top:287.3pt;left:82.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">It is FDA approved for the treatment of certain hematological malignancies. Several promising</span></p>
<p style="top:300.8pt;left:82.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">o</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">-target drug e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ects have led to multiple, mostly preclinical investigations regarding its use in</span></p>
<p style="top:314.3pt;left:82.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">solid tumors. Unfortunately, data on its e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ectiveness in gynecological malignancies are limited,</span></p>
<p style="top:327.8pt;left:82.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and (systematic) reviews are missing. The objective of this review was to summarize the existing</span></p>
<p style="top:341.5pt;left:82.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">literature and to analyze the evidence of ibrutinib as a treatment option in gynecological malignancies,</span></p>
<p style="top:354.9pt;left:82.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">including breast cancer. Studies were identi&#xfb01;ed in MEDLINE and EMBASE using a de&#xfb01;ned search</span></p>
<p style="top:368.4pt;left:82.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">strategy, and preclinical or clinical research projects investigating ibrutinib in connection with these</span></p>
<p style="top:381.8pt;left:82.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">malignancies were considered eligible for inclusion. Our &#xfb01;ndings showed that preclinical studies</span></p>
<p style="top:395.5pt;left:82.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">generally con&#xfb01;rm ibrutinib&#x2019;s e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">cacy in cell lines and animal models of ovarian, breast, and endometrial</span></p>
<p style="top:408.9pt;left:82.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">cancer. Ibrutinib exerts multiple antineoplastic e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ects, such as on-target BTK inhibition, o</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">-target</span></p>
<p style="top:422.4pt;left:82.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">kinase inhibition, and immunomodulation by interference with myeloid-derived suppressor cells</span></p>
<p style="top:435.9pt;left:81.9pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">(MDSCs), programmed death-ligand 1 (PD-L1), and T cell response. These mechanisms were</span></p>
<p style="top:449.5pt;left:82.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">elaborated and discussed in the context of the evidence available. Further research is needed in order</span></p>
<p style="top:463.0pt;left:82.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">to transfer the preclinical results to a broader clinical appliance.</span></p>
<p style="top:488.4pt;left:82.2pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Keywords:</span></b><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> ibrutinib; Bruton&#x2019;s tyrosine kinase; Btk; kinase inhibitor; ovarian cancer; endometrial cancer;</span></p>
<p style="top:501.9pt;left:82.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">breast cancer; gynecology; gynecologic oncology; solid tumors</span></p>
<p style="top:552.9pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">1. Introduction</span></b></p>
<p style="top:572.5pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">This publication o</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ered a systematic review of ibrutinib&#x2019;s current use in gynecological malignancies.</span></p>
<p style="top:585.9pt;left:76.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">The article is structured in three parts. After a conceptual and terminological introduction to the drug</span></p>
<p style="top:599.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">and the diseases, genes, and proteins covered (I); we next reviewed the existing literature on ibrutinib&#x2019;s</span></p>
<p style="top:612.8pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">use in gynecological malignancies, including breast cancer (II); Finally, we analyzed the results and</span></p>
<p style="top:626.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">discussed ibrutinib&#x2019;s multiple mechanisms of action in the context of the literature available (III).</span></p>
<p style="top:639.8pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Ibrutinib is an orally available, small-molecule tyrosine kinase inhibitor. Its main purpose is</span></p>
<p style="top:653.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">to inhibit Bruton&#x2019;s tyrosine kinase (BTK), a crucial enzyme in the B cell antigen receptor signaling</span></p>
<p style="top:666.9pt;left:76.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">pathway [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">1</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">3</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. BTK is a member of the TEC-family kinases (TEC, BTK, BMX, ITK, RLK), a group of</span></p>
<p style="top:680.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">non-receptor kinases that modulate intracellular signaling in B- and T-cells and a</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ect cell proliferation,</span></p>
<p style="top:694.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">survival, and di</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">erentiation in various cell types [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">4</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Ibrutinib blocks BTK by forming covalent bonds</span></p>
<p style="top:707.5pt;left:76.1pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">with cysteine 481 near the ATP binding pocket of the enzyme, resulting in an irreversible inactivation</span></p>
<p style="top:720.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and suppression of downstream e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ectors [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">2</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">4</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. In this setting, ibrutinib is FDA approved for the</span></p>
<p style="top:734.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">treatment of adult patients with hematological diseases, such as mantle cell lymphoma (MCL), chronic</span></p>
<p style="top:748.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom&#x2019;s macroglobulinemia</span></p>
<p style="top:761.5pt;left:76.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">(WM), marginal zone lymphoma (MZL), and chronic graft versus host disease (cGVHD) [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">5</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:793.0pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 4154; doi:10.3390</span><span style="font-family:Rpxr,serif;font-size:8.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">ijms21114154</span></p>
<p style="top:793.0pt;left:417.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">www.mdpi.com</span><span style="font-family:Rpxr,serif;font-size:8.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">journal</span><span style="font-family:Rpxr,serif;font-size:8.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">ijms</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 4154</span></p>
<p style="top:56.6pt;left:495.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2 of 17</span></p>
<p style="top:89.9pt;left:97.7pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Besides its well-known and approved effectiveness in hematology, ibrutinib shows some promising</span></p>
<p style="top:103.4pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">off-target potential due to its efficacy on additional binding sites and enzymes, including tyrosine kinases</span></p>
<p style="top:117.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">that conserve the same Cys481 residue, such as the ERBB family (EGFR, ERBB2</span><span style="font-family:Rpxr,serif;font-size:9.9pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">HER2, et al.) [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">2</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. This has led</span></p>
<p style="top:130.4pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">to several, mostly, preclinical publications, investigating its use in solid tumors [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">4</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">6</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">8</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. With an increasing</span></p>
<p style="top:144.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">number of research papers addressing this topic, and new kinase inhibitors (such as neratinib) being legally</span></p>
<p style="top:157.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">approved in this field, the effectiveness of ibrutinib in the treatment of gynecological malignancies and</span></p>
<p style="top:170.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">breast cancer seems plausible, although summarized evidence is missing.</span></p>
<p style="top:184.4pt;left:97.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Ibrutinib&#x2019;s toxicity is mainly explained by its inhibition of related kinases. EGFR inhibition may</span></p>
<p style="top:197.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">cause rash and diarrhea. Its more serious unwanted e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ects include cardiac events (atrial &#xfb01;brillation,</span></p>
<p style="top:211.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">rarely ventricular arrhythmia) and bleeding, as BTK and TEC modulate platelet aggregation [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">9</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">11</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">].</span></p>
<p style="top:224.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Further and frequently described side e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ects include digestive and myelosuppressive disorders,</span></p>
<p style="top:238.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">hypertension, edema, fatigue, and infections [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">4</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. The side e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ects are generally well manageable,</span></p>
<p style="top:251.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and combinations of ibrutinib with multiple chemotherapeutic agents and monoclonal antibodies</span></p>
<p style="top:265.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">are safe [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">3</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">12</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">14</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. The dosage depends on the underlying disease and ranges from 420 mg daily in</span></p>
<p style="top:278.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">CLL</span><span style="font-family:Rpxr,serif;font-size:10.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">WM to 560 in MCL. In current trials on solid tumors, daily doses from 420 to 840 mg are being</span></p>
<p style="top:292.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">administered [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">15</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">17</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Dose reductions are recommended after certain recurrent toxicities</span><span style="font-family:Pxsy,serif;font-size:10.0pt"> &#x2265;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> CTCAE 3</span><sup><span style="font-family:Pxsy,serif;font-size:7.6pt">&#x25e6;</span></sup><span style="font-family:URWPalladioL,serif;font-size:9.9pt">.</span></p>
<p style="top:306.1pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">The nonspeci&#xfb01;city of ibrutinib has led to the development of several second-generation irreversible</span></p>
<p style="top:319.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">BTK inhibitors [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">18</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Acalabrutinib is FDA approved for adults with MCL, CLL, and SLL [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">19</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. It inherits</span></p>
<p style="top:333.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">a higher sensitivity to BTK, while it has little or no inhibitory e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ect on other kinases, such as ITK, EGFR,</span></p>
<p style="top:346.5pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ERBB2, ERBB4, JAK3, BLK, FGR, HCK, LCK, SRC, and YES1 [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">20</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">21</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Further compounds include</span></p>
<p style="top:360.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">zanubrutinib (FDA approved for the treatment of MCL [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">22</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]), tirabrutinib, spebrutinib, and evobrutinib.</span></p>
<p style="top:373.5pt;left:76.1pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">All of these drugs show a di</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">erent selectivity pro&#xfb01;le against o</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">-target enzymes and are mainly</span></p>
<p style="top:387.0pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">investigated in B cell malignancies or autoimmune diseases [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">23</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">25</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. While the reduced o</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">-target</span></p>
<p style="top:400.7pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">activities of these second-generation BTK inhibitors are thought to minimize side e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ects [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">9</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">], this might</span></p>
<p style="top:414.0pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">arguably also minimize their e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ect on solid malignancies when compared to ibrutinib. As shown</span></p>
<p style="top:427.6pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">below, many of ibrutinib&#x2019;s antineoplastic mechanisms in solid tumors rely on its kinase promiscuity</span></p>
<p style="top:441.2pt;left:76.1pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">with e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">cacy on enzymes, such as EGFR and ERBB2. Furthermore, data on the e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">cacy of these newer</span></p>
<p style="top:454.6pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">compounds on diseases outside of the hematological spectrum are scarce or missing. Hence, this</span></p>
<p style="top:468.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">review focused on publications investigating ibrutinib.</span></p>
<p style="top:481.6pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Ovarian cancer is one of the leading causes of death from gynecological cancers in developed</span></p>
<p style="top:495.2pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">countries, with a 5-year survival rate of less than 50% after initial diagnosis. First-line therapy includes</span></p>
<p style="top:508.7pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">a combination of surgical tumor resection and platinum-based chemotherapy [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">26</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Current guidelines</span></p>
<p style="top:522.2pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">recommend the subsequent use of maintenance therapy with a poly-ADP-ribose-polymerase (PARP)</span></p>
<p style="top:535.6pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">inhibitor in a selected group of patients with stage II&#x2013;IV disease and BRCA1</span><span style="font-family:Rpxr,serif;font-size:10.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">2 mutations, who are</span></p>
<p style="top:549.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in complete or partial remission after primary surgery and chemotherapy [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">26</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Therapy response is</span></p>
<p style="top:562.8pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">commonly monitored by measuring levels of CA-125, which is also used to detect residual or recurrent</span></p>
<p style="top:576.2pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">disease, as well as clinical decision-making regarding imaging and second-look procedures [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">27</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:589.6pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">In cases of recurrent disease,</span></p>
<p style="top:589.6pt;left:251.9pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">a distinction is made between platinum-sensitive and</span></p>
<p style="top:603.2pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">platinum-resistant recurrence. The classical de&#xfb01;nition of platinum sensitivity is recurrence after</span></p>
<p style="top:616.7pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">a platinum-free interval of</span><span style="font-family:Pxsya,serif;font-size:10.0pt"> &#x2a7e;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> 6 months. There has been some recent controversy regarding this</span></p>
<p style="top:630.2pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">old de&#xfb01;nition, questioning whether a de&#xfb01;nition based on the response to platinum would be more</span></p>
<p style="top:643.8pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">biologically relevant [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">28</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">29</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:657.2pt;left:97.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">In cases of platinum-sensitive recurrence, a similar approach of cytoreductive surgery followed</span></p>
<p style="top:670.8pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">by platinum-based chemotherapy is used. Platinum-resistance is typically seen after prolonged use of</span></p>
<p style="top:684.3pt;left:76.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">platinum-based chemotherapy due to the development of platinum-resistant clones. In this situation,</span></p>
<p style="top:697.7pt;left:76.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">platinum-free cytotoxic regimens, targeted agents, and</span><span style="font-family:Rpxr,serif;font-size:10.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">or best supportive care are recommended in</span></p>
<p style="top:711.3pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">cases of radiological or clinical relapse [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">30</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. In cases with a purely &#x201c;biochemical relapse&#x201d; (increasing</span></p>
<p style="top:724.7pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">CA-125 without radiologic or clinical evidence of the disease), treatment can be delayed until the</span></p>
<p style="top:738.3pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">occurrence of symptoms [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">30</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 4154</span></p>
<p style="top:56.6pt;left:495.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3 of 17</span></p>
<p style="top:89.9pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Breast cancer is the most common cancer in the female population, accounting for almost a third</span></p>
<p style="top:103.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">of all newly diagnosed cancers in women. Despite great advancements in therapy, it remains the</span></p>
<p style="top:116.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">second leading cause of cancer-related deaths in women due to its high incidence [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">31</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:130.3pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Breast cancer is typically categorized into subtypes, depending on the expression of hormone</span></p>
<p style="top:144.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">receptors (estrogen, progesterone) and of human epidermal growth factor 2 (HER2</span><span style="font-family:Rpxr,serif;font-size:9.9pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ERBB2). The three</span></p>
<p style="top:157.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">major subtypes, namely, hormone-receptor-positive</span><span style="font-family:Rpxr,serif;font-size:10.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">HER2-negative cancers (70%), HER2-positive</span></p>
<p style="top:171.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">cancers (15&#x2013;20%), and triple-negative cancers (15%), vary in prognosis but o</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">er distinctive options for</span></p>
<p style="top:184.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">targeted or systemic treatment [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">32</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:197.9pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Over 90% of patients present with the non-metastatic disease at diagnosis and are treated</span></p>
<p style="top:211.4pt;left:76.1pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">with curative intent.</span></p>
<p style="top:211.4pt;left:178.9pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">This usually consists of a local (surgical tumor resection) and a systemic</span></p>
<p style="top:225.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">therapy according to the molecular subtype, including endocrine treatment, antibodies against HER2,</span></p>
<p style="top:238.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">and chemotherapy, with a trend towards neoadjuvant systemic treatment in recent years. Adjuvant</span></p>
<p style="top:252.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">radiotherapy is usually recommended after breast-conserving surgery [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">32</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:265.4pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">In cases of metastatic disease,</span></p>
<p style="top:265.4pt;left:257.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">treatment is palliative and depends on the subtype.</span></p>
<p style="top:278.9pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Therapeutic choices include endocrine treatment and cyclin-dependent kinase inhibitors for</span></p>
<p style="top:292.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">hormone-receptor-positive subtypes, HER2-targeted antibodies, antibody compounds or tyrosine</span></p>
<p style="top:306.0pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">kinase inhibitors for HER2-positive tumors, and chemotherapy. Radiotherapy can be used for local</span></p>
<p style="top:319.5pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">disease control. Recently, the availability of immunotherapy targeting PD-1 and PD-L1 has led to</span></p>
<p style="top:333.0pt;left:76.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">promising e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ects in HER2</span><sup><span style="font-family:Rpxr,serif;font-size:7.6pt">+</span></sup><sup><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> </span></sup><span style="font-family:URWPalladioL,serif;font-size:10.0pt">and triple-negative breast cancer.</span></p>
<p style="top:356.3pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">2. Results</span></b></p>
<p style="top:379.5pt;left:76.5pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">2.1. Overview</span></i></p>
<p style="top:398.9pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Of the 92 search results, 12 articles were excluded due to the selection criteria or duplication.</span></p>
<p style="top:412.4pt;left:76.1pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">After the abstract</span><span style="font-family:Rpxr,serif;font-size:10.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">full-text assessment, 69 were excluded because they were unrelated to the topic.</span></p>
<p style="top:425.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Eleven publications were selected as eligible for inclusion. Figure</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt;color:#0774b7"> 1</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> shows the &#xfb02;ow diagram for the</span></p>
<p style="top:439.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">identi&#xfb01;cation of relevant studies. In this results section, the evidence available on the e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">cacy of ibrutinib</span></p>
<p style="top:453.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in breast cancer and gynecological malignancy, as summarized in Tables</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7"> 1</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">3</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">, has been reviewed.</span></p>
<p style="top:476.2pt;left:76.5pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">2.2. Review of Identi&#xfb01;ed Studies</span></i></p>
<p style="top:499.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">2.2.1. Breast Cancer</span></p>
<p style="top:518.9pt;left:97.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">In 2014,</span><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> Grabinski and Ewald</span></b><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">33</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">] tested the e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">cacy of ibrutinib (alone or in combination with</span></p>
<p style="top:532.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">dactolisib, a PI3K</span><span style="font-family:Rpxr,serif;font-size:9.9pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">mTOR inhibitor) on ten di</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">erent subtypes of breast cancer cells</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vitro</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">. Cell viability</span></p>
<p style="top:546.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">after treatment with di</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">erent concentrations of ibrutinib was measured. While ER</span><span style="font-family:Rpxr,serif;font-size:9.9pt">+</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> and triple-negative</span></p>
<p style="top:559.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">cell lines were not signi&#xfb01;cantly attenuated after drug treatment, a signi&#xfb01;cant reduction in the viability</span></p>
<p style="top:572.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">of HER2</span><sup><span style="font-family:Rpxr,serif;font-size:7.6pt">+</span></sup><sup><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> </span></sup><span style="font-family:URWPalladioL,serif;font-size:10.0pt">cell lines was demonstrated, even with low drug concentrations (half-maximal inhibitory</span></p>
<p style="top:586.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">concentration IC50 in the lower nanomolar range). Speci&#xfb01;c inhibition of the phosphorylation of the</span></p>
<p style="top:599.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">cancer-related signaling pathway AKT in HER2</span><sup><span style="font-family:Rpxr,serif;font-size:7.6pt">+</span></sup><sup><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> </span></sup><span style="font-family:URWPalladioL,serif;font-size:10.0pt">cells was demonstrated and was postulated as the</span></p>
<p style="top:613.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">underlying mechanism of action. The addition of the dual PI3K</span><span style="font-family:Rpxr,serif;font-size:10.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">mTOR inhibitor dactolisib further</span></p>
<p style="top:627.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">reduced cell viability in a synergistic manner. Moreover, ibrutinib reduced the phosphorylation and</span></p>
<p style="top:640.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">downstream signaling of the EGFR receptors&#x2014;ErbB1, ErbB2, and ErbB3. In summary, the study</span></p>
<p style="top:654.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">suggested a potential use of ibrutinib in HER2</span><sup><span style="font-family:Rpxr,serif;font-size:7.6pt">+</span></sup><sup><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> </span></sup><span style="font-family:URWPalladioL,serif;font-size:10.0pt">breast cancer.</span></p>
<p style="top:667.5pt;left:97.8pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Sagiv-Bar&#xfb01;</span></b><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> et al. [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">34</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">] investigated the synergistic e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ects of ibrutinib in combination with anti-PD-L1</span></p>
<p style="top:680.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">antibodies on di</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">erent cell lines, including 4t1-Luc, a triple-negative breast cancer (TNBC) cell line.</span></p>
<p style="top:694.5pt;left:76.1pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">As 4T1-cells express low levels of PD-L1 only and no BTK, no single drug showed any e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ect on</span></p>
<p style="top:708.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">tumor viability</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vitro</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> or in 4T1-xenografted mice. However, a reduction in tumor size, fewer lung</span></p>
<p style="top:721.5pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">metastases, and an increased survival along with the generation of speci&#xfb01;c antitumor T-cells were</span></p>
<p style="top:735.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">observed with a combined treatment of ibrutinib and anti-PD-L1.</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 4154</span></p>
<p style="top:56.6pt;left:495.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">4 of 17</span></p>
<p style="top:89.8pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Given the fact that ibrutinib may have relevant HER2 targeting activity,</span><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> Chen et al.</span></b><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">2</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">] sought</span></p>
<p style="top:103.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">to address several critical questions regarding its potential clinical use in HER2-overexpressing</span></p>
<p style="top:116.8pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">breast cancer through growth inhibition experiments, apoptosis assays, xenograft mouse models,</span></p>
<p style="top:130.5pt;left:76.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">pharmacokinetics</span><span style="font-family:Rpxr,serif;font-size:9.9pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">pharmacodynamics, immunohistochemical analysis, Western blot analysis, cell cycle</span></p>
<p style="top:143.8pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">assay, BTK occupancy assays, and kinase assays. In these experiments, they were able to show that</span></p>
<p style="top:157.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ibrutinib demonstrated antiproliferative activity against certain solid tumor cell lines, similar to the</span></p>
<p style="top:170.9pt;left:76.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">previously published patterns of the known EGFR inhibitors&#x2014;ge&#xfb01;tinib and lapatinib. Cell lines that</span></p>
<p style="top:184.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">depend on HER2 for their proliferation were most sensitive. Mechanistically, the compound was</span></p>
<p style="top:197.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">found to inhibit phosphorylation and downstream signaling of HER2 and EGFR in these cell lines at</span></p>
<p style="top:211.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">concentrations in the nanomolar range, mirroring the e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ect of other HER2 inhibitors. In comparison to</span></p>
<p style="top:225.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">the potency of other ERBB kinase inhibitors, ibrutinib had a higher potency than lapatinib and ge&#xfb01;tinib,</span></p>
<p style="top:238.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">albeit lower than afatinib and neratinib.</span></p>
<p style="top:252.1pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">In a series of xenograft studies with HER2</span><sup><span style="font-family:Rpxr,serif;font-size:7.6pt">+</span></sup><sup><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> </span></sup><span style="font-family:URWPalladioL,serif;font-size:9.9pt">cell lines in mice, ibrutinib slowed tumor progress up</span></p>
<p style="top:265.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">to 90% in a dose-dependent manner in certain series. The maximum e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ect was seen in mice strains</span></p>
<p style="top:278.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">that achieved a higher drug exposure (probably due to di</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">erences in bioavailability), as revealed</span></p>
<p style="top:292.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">by pharmacokinetics. As a promising outlook, the calculated AUC (area under the plasma drug</span></p>
<p style="top:306.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">concentration-time curve) for tumor growth inhibition seemed achievable in humans with a standard</span></p>
<p style="top:319.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">560 mg per day dosing.</span></p>
<p style="top:318.0pt;left:79.6pt;line-height:8.0pt"><i><span style="font-family:PalatinoLinotype,Italic,serif;font-size:8.0pt">Int. J. Mol. Sci. </span></i><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:8.0pt">2020</span></b><span style="font-family:PalatinoLinotype,serif;font-size:8.0pt">, </span><i><span style="font-family:PalatinoLinotype,Italic,serif;font-size:8.0pt">21</span></i><span style="font-family:PalatinoLinotype,serif;font-size:8.0pt">, x FOR PEER REVIEW </span></p>
<p style="top:318.0pt;left:495.7pt;line-height:8.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:8.0pt">4 of 17 </span></p>
<p style="top:684.4pt;left:450.1pt;line-height:12.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:12.0pt"> </span></p>
<p style="top:706.4pt;left:173.0pt;line-height:9.0pt"><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:9.0pt">Figure 1.</span></b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt"> Flow diagram for the identification of relevant studies. </span></p>
<p style="top:730.8pt;left:79.6pt;line-height:10.0pt"><i><span style="font-family:PalatinoLinotype,Italic,serif;font-size:10.0pt">2.2. Review of Identified Studies </span></i></p>
<p style="top:756.3pt;left:79.6pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">2.2.1. Breast Cancer </span></p>
<p style="top:781.8pt;left:100.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">In 2014, </span><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:10.0pt">Grabinski and Ewald</span></b><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt"> [33] tested the efficacy of ibrutinib (alone or in combination with </span></p>
<p style="top:795.3pt;left:79.6pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">dactolisib, a PI3K/mTOR inhibitor) on ten different subtypes of breast cancer cells in vitro. Cell </span></p>
<p style="top:808.8pt;left:79.6pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">viability after treatment with different concentrations of ibrutinib was measured. While ER+ and </span></p>
<p style="top:822.3pt;left:79.6pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">triple-negative cell lines were not significantly attenuated after drug treatment, a significant </span></p>
<p style="top:835.8pt;left:79.6pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">reduction in the viability of HER2</span><sup><span style="font-family:PalatinoLinotype,serif;font-size:6.0pt">+</span></sup><sup><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt"> </span></sup><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">cell lines was demonstrated even with low drug concentrations</span></p>
<img style="position:absolute;transform:matrix(.32,0,-0,.31978203,-221.94934,206.36817)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.32,0,-0,.32021827,-221.94934,442.08815)" src="data:image/png;base64,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">
<p style="top:703.7pt;left:170.2pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Figure 1.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Flow diagram for the identi&#xfb01;cation of relevant studies.</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 4154</span></p>
<p style="top:56.6pt;left:495.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">5 of 17</span></p>
<p style="top:89.7pt;left:161.1pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Table 1.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Current evidence of the e</span><span style="font-family:Rpxr,serif;font-size:9.0pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">cacy of ibrutinib in breast cancer.</span></p>
<p style="top:109.8pt;left:90.9pt;line-height:6.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.9pt">First Author</span></b></p>
<p style="top:118.3pt;left:101.4pt;line-height:6.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.9pt">[Ref.]</span></b></p>
<p style="top:114.0pt;left:151.9pt;line-height:6.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Year</span></b></p>
<p style="top:114.0pt;left:189.4pt;line-height:6.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Study Type</span></b></p>
<p style="top:114.0pt;left:245.7pt;line-height:6.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Model</span></b></p>
<p style="top:114.0pt;left:289.2pt;line-height:6.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Histology</span></b></p>
<p style="top:114.0pt;left:336.8pt;line-height:6.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Outcome Measures</span></b></p>
<p style="top:114.0pt;left:432.2pt;line-height:6.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Main Outcomes</span></b></p>
<p style="top:172.6pt;left:95.1pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Grabinski</span></p>
<p style="top:172.6pt;left:151.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">2014</span></p>
<p style="top:168.4pt;left:191.1pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Preclinical:</span></p>
<p style="top:176.8pt;left:196.3pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">in vitro</span></p>
<p style="top:172.6pt;left:238.3pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Cell culture</span></p>
<p style="top:168.4pt;left:285.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Breast cancer</span></p>
<p style="top:176.8pt;left:291.3pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">(HER2</span><sup><span style="font-family:Rpxr,serif;font-size:5.4pt">+</span></sup><span style="font-family:URWPalladioL,serif;font-size:6.9pt">)</span></p>
<p style="top:159.9pt;left:347.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Cell viability,</span></p>
<p style="top:168.4pt;left:337.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">phosphorylation of</span></p>
<p style="top:176.8pt;left:341.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">receptor tyrosine</span></p>
<p style="top:185.3pt;left:356.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">kinases</span></p>
<p style="top:130.4pt;left:416.1pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Signi&#xfb01;cant reduction in the</span></p>
<p style="top:138.8pt;left:414.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">viability of HER2</span><sup><span style="font-family:Rpxr,serif;font-size:5.4pt">+</span></sup><sup><span style="font-family:URWPalladioL,serif;font-size:6.9pt"> </span></sup><span style="font-family:URWPalladioL,serif;font-size:6.9pt">cell lines</span></p>
<p style="top:147.3pt;left:433.2pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">due to ibrutinib.</span></p>
<p style="top:155.7pt;left:435.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">IC50 values at</span></p>
<p style="top:164.2pt;left:417.3pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">nanomolar concentrations.</span></p>
<p style="top:172.6pt;left:421.2pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Synergistic cell viability</span></p>
<p style="top:181.0pt;left:417.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">reduction of ibrutinib and</span></p>
<p style="top:189.5pt;left:438.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">PI3K</span><span style="font-family:Rpxr,serif;font-size:6.9pt">/</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt">mTOR</span></p>
<p style="top:197.9pt;left:428.2pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">inhibitor dactolisib.</span></p>
<p style="top:206.3pt;left:425.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Reduced MAPK and</span></p>
<p style="top:214.8pt;left:422.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">AKT phosphorylation.</span></p>
<p style="top:248.0pt;left:93.3pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Sagiv-Bar&#xfb01;</span></p>
<p style="top:248.0pt;left:151.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">2015</span></p>
<p style="top:235.4pt;left:191.1pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Preclinical:</span></p>
<p style="top:243.8pt;left:193.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">in vitro</span><span style="font-family:Rpxr,serif;font-size:6.9pt"> +</span></p>
<p style="top:252.2pt;left:196.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">in vivo</span></p>
<p style="top:260.7pt;left:194.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">(animal)</span></p>
<p style="top:235.4pt;left:237.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Cell culture,</span></p>
<p style="top:243.8pt;left:241.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">xenograft</span></p>
<p style="top:252.2pt;left:245.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">mouse</span></p>
<p style="top:260.7pt;left:246.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">model</span></p>
<p style="top:243.8pt;left:285.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Breast cancer</span></p>
<p style="top:252.2pt;left:292.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">(TNBC)</span></p>
<p style="top:235.4pt;left:347.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Cell viability,</span></p>
<p style="top:243.8pt;left:350.6pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">tumor size,</span></p>
<p style="top:252.2pt;left:340.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">no. of metastases;</span></p>
<p style="top:260.7pt;left:342.2pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Animal survival</span></p>
<p style="top:226.9pt;left:412.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Combination of ibrutinib and</span></p>
<p style="top:235.4pt;left:415.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">anti&#x2013;PD-L1 inhibits growth</span></p>
<p style="top:243.8pt;left:443.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">of TNBC.</span></p>
<p style="top:252.2pt;left:418.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">The combination therapy</span></p>
<p style="top:260.7pt;left:414.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">generates speci&#xfb01;c antitumor</span></p>
<p style="top:269.1pt;left:446.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">T cells.</span></p>
<p style="top:310.8pt;left:102.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Chen</span></p>
<p style="top:310.8pt;left:151.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">2016</span></p>
<p style="top:298.1pt;left:191.1pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Preclinical:</span></p>
<p style="top:306.6pt;left:193.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">in vitro</span><span style="font-family:Rpxr,serif;font-size:6.9pt"> +</span></p>
<p style="top:315.0pt;left:196.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">in vivo</span></p>
<p style="top:323.4pt;left:194.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">(animal)</span></p>
<p style="top:298.1pt;left:237.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Cell culture,</span></p>
<p style="top:306.6pt;left:241.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">xenograft</span></p>
<p style="top:315.0pt;left:245.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">mouse</span></p>
<p style="top:323.4pt;left:246.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">model</span></p>
<p style="top:306.6pt;left:285.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Breast cancer</span></p>
<p style="top:315.0pt;left:292.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">(Her2</span><sup><span style="font-family:Rpxr,serif;font-size:5.4pt">+</span></sup><span style="font-family:URWPalladioL,serif;font-size:6.9pt">)</span></p>
<p style="top:302.3pt;left:347.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Cell viability,</span></p>
<p style="top:310.8pt;left:350.6pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">tumor size,</span></p>
<p style="top:319.2pt;left:345.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">drug exposure</span></p>
<p style="top:281.3pt;left:419.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Inhibition of growth and</span></p>
<p style="top:289.7pt;left:413.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">suppression of key signaling</span></p>
<p style="top:298.1pt;left:416.6pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">pathways in HER2</span><sup><span style="font-family:Rpxr,serif;font-size:5.4pt">+</span></sup><sup><span style="font-family:URWPalladioL,serif;font-size:6.9pt"> </span></sup><span style="font-family:URWPalladioL,serif;font-size:6.9pt">breast</span></p>
<p style="top:306.6pt;left:433.3pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">cancer cell lines.</span></p>
<p style="top:315.0pt;left:417.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Clinically achievable drug</span></p>
<p style="top:323.4pt;left:410.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">levels suppress HER2</span><sup><span style="font-family:Rpxr,serif;font-size:5.4pt">+</span></sup><sup><span style="font-family:URWPalladioL,serif;font-size:6.9pt"> </span></sup><span style="font-family:URWPalladioL,serif;font-size:6.9pt">human</span></p>
<p style="top:331.9pt;left:421.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">breast cancer growth in</span></p>
<p style="top:340.3pt;left:418.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">xenograft mouse models.</span></p>
<p style="top:386.2pt;left:104.1pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Sti</span><span style="font-family:Rpxr,serif;font-size:6.9pt">&#xfb00;</span></p>
<p style="top:386.2pt;left:151.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">2016</span></p>
<p style="top:373.6pt;left:191.1pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Preclinical:</span></p>
<p style="top:382.0pt;left:193.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">in vitro</span><span style="font-family:Rpxr,serif;font-size:6.9pt"> +</span></p>
<p style="top:390.4pt;left:196.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">in vivo</span></p>
<p style="top:398.9pt;left:194.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">(animal)</span></p>
<p style="top:373.6pt;left:237.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Cell culture,</span></p>
<p style="top:382.0pt;left:241.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">xenograft</span></p>
<p style="top:390.4pt;left:245.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">mouse</span></p>
<p style="top:398.9pt;left:246.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">model</span></p>
<p style="top:382.0pt;left:285.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Breast cancer</span></p>
<p style="top:390.4pt;left:292.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">(TNBC)</span></p>
<p style="top:373.6pt;left:342.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">BTK expression,</span></p>
<p style="top:382.0pt;left:339.6pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">MDSCs frequency</span></p>
<p style="top:390.4pt;left:341.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">in vivo (by IHC),</span></p>
<p style="top:398.9pt;left:351.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">tumor size</span></p>
<p style="top:352.5pt;left:414.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Human and murine MDSCs</span></p>
<p style="top:360.9pt;left:438.2pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">express BTK.</span></p>
<p style="top:369.3pt;left:414.1pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Ibrutinib modulates MDSCs&#x2019;</span></p>
<p style="top:377.8pt;left:414.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">cell function and generation</span></p>
<p style="top:386.2pt;left:417.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">and diminishes MDSCs in</span></p>
<p style="top:394.6pt;left:426.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">tumor-bearing mice.</span></p>
<p style="top:403.1pt;left:411.6pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Ibrutinib potentially enhances</span></p>
<p style="top:411.5pt;left:415.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">immune-based therapies in</span></p>
<p style="top:420.0pt;left:428.1pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">solid malignancies.</span></p>
<p style="top:453.2pt;left:98.2pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Wang X</span></p>
<p style="top:453.2pt;left:151.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">2016</span></p>
<p style="top:440.5pt;left:191.1pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Preclinical:</span></p>
<p style="top:449.0pt;left:193.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">in vitro</span><span style="font-family:Rpxr,serif;font-size:6.9pt"> +</span></p>
<p style="top:457.4pt;left:196.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">in vivo</span></p>
<p style="top:465.9pt;left:197.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">(mice)</span></p>
<p style="top:440.5pt;left:237.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Cell culture,</span></p>
<p style="top:449.0pt;left:241.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">xenograft</span></p>
<p style="top:457.4pt;left:245.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">mouse</span></p>
<p style="top:465.9pt;left:246.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">model</span></p>
<p style="top:449.0pt;left:285.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Breast cancer</span></p>
<p style="top:457.4pt;left:292.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">(Her2</span><sup><span style="font-family:Rpxr,serif;font-size:5.4pt">+</span></sup><span style="font-family:URWPalladioL,serif;font-size:6.9pt">)</span></p>
<p style="top:449.0pt;left:347.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Cell viability,</span></p>
<p style="top:457.4pt;left:351.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">tumor size</span></p>
<p style="top:432.1pt;left:417.2pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Ibrutinib is more potent in</span></p>
<p style="top:440.5pt;left:416.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">inhibiting HER2</span><sup><span style="font-family:Rpxr,serif;font-size:5.4pt">+</span></sup><sup><span style="font-family:URWPalladioL,serif;font-size:6.9pt"> </span></sup><span style="font-family:URWPalladioL,serif;font-size:6.9pt">cell than</span></p>
<p style="top:449.0pt;left:443.6pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">lapatinib.</span></p>
<p style="top:457.4pt;left:412.3pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Ibrutinib blocks EGFR, HER2,</span></p>
<p style="top:465.9pt;left:429.1pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">ErbB3, ErbB4 at its</span></p>
<p style="top:474.3pt;left:423.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">downstream e</span><span style="font-family:Rpxr,serif;font-size:6.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt">ectors.</span></p>
<p style="top:503.3pt;left:106.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Di</span></p>
<p style="top:503.3pt;left:151.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">2019</span></p>
<p style="top:499.1pt;left:191.1pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Preclinical:</span></p>
<p style="top:507.6pt;left:187.7pt;line-height:6.8pt"><span style="font-family:URWPalladioL,serif;font-size:6.8pt">bioinformatics</span></p>
<p style="top:490.6pt;left:248.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Drug</span></p>
<p style="top:499.1pt;left:240.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">functional</span></p>
<p style="top:507.5pt;left:241.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">similarity</span></p>
<p style="top:516.0pt;left:243.2pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">network</span></p>
<p style="top:494.9pt;left:285.0pt;line-height:6.8pt"><span style="font-family:URWPalladioL,serif;font-size:6.8pt">Breast cancer,</span></p>
<p style="top:503.3pt;left:293.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">ovarian</span></p>
<p style="top:511.7pt;left:294.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">cancer</span></p>
<p style="top:499.1pt;left:342.1pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Prior score, false</span></p>
<p style="top:507.5pt;left:345.6pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">discovery rate</span></p>
<p style="top:486.4pt;left:419.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Ibrutinib ranks 3rd in the</span></p>
<p style="top:494.9pt;left:415.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">prioritized list of candidate</span></p>
<p style="top:503.3pt;left:417.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">breast cancer drugs and is</span></p>
<p style="top:511.7pt;left:420.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">considered to have great</span></p>
<p style="top:520.2pt;left:432.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">potential e</span><span style="font-family:Rpxr,serif;font-size:6.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt">ects.</span></p>
<p style="top:561.8pt;left:101.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Hong</span></p>
<p style="top:561.8pt;left:151.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">2019</span></p>
<p style="top:561.8pt;left:191.2pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Phase Ib</span><span style="font-family:Rpxr,serif;font-size:6.9pt">/</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt">II</span></p>
<p style="top:561.8pt;left:244.3pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Human</span></p>
<p style="top:540.8pt;left:285.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Breast cancer</span></p>
<p style="top:549.2pt;left:293.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">(TNBC,</span></p>
<p style="top:557.6pt;left:292.1pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">HER2</span><sup><span style="font-family:Rpxr,serif;font-size:5.4pt">+</span></sup><span style="font-family:URWPalladioL,serif;font-size:6.9pt">),</span></p>
<p style="top:566.1pt;left:288.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">pancreatic</span></p>
<p style="top:574.5pt;left:294.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">cancer,</span></p>
<p style="top:582.9pt;left:293.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">NSCLC</span></p>
<p style="top:549.2pt;left:334.3pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Overall response rate,</span></p>
<p style="top:557.6pt;left:342.2pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">progression-free</span></p>
<p style="top:566.1pt;left:354.2pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">survival,</span></p>
<p style="top:574.5pt;left:343.2pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">overall survival</span></p>
<p style="top:532.3pt;left:413.6pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Recommended phase 2 dose:</span></p>
<p style="top:540.8pt;left:423.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">560 mg ibrutinib daily,</span></p>
<p style="top:549.2pt;left:410.6pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">durvalumab 10 mg</span><span style="font-family:Rpxr,serif;font-size:6.9pt">/</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt">kg i.v. q2w.</span></p>
<p style="top:557.6pt;left:411.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">ORR: 3% for breast cancer; 2%</span></p>
<p style="top:566.1pt;left:419.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">for pancreatic cancer; 0%</span></p>
<p style="top:574.5pt;left:440.2pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">for NSCLC.</span></p>
<p style="top:582.9pt;left:416.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Limited antitumor activity;</span></p>
<p style="top:591.4pt;left:419.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">acceptable safety pro&#xfb01;le.</span></p>
<p style="top:641.5pt;left:97.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Varikuti</span></p>
<p style="top:641.5pt;left:151.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">2020</span></p>
<p style="top:633.1pt;left:191.1pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Preclinical:</span></p>
<p style="top:641.5pt;left:196.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">in vivo</span></p>
<p style="top:649.9pt;left:194.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">(animal)</span></p>
<p style="top:628.8pt;left:237.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Cell culture,</span></p>
<p style="top:637.3pt;left:241.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">xenograft</span></p>
<p style="top:645.7pt;left:245.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">mouse</span></p>
<p style="top:654.1pt;left:246.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">model</span></p>
<p style="top:637.3pt;left:285.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Breast cancer</span></p>
<p style="top:645.7pt;left:286.3pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">(Luminal B)</span></p>
<p style="top:616.2pt;left:347.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Cell viability,</span></p>
<p style="top:624.6pt;left:350.6pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">tumor size,</span></p>
<p style="top:633.1pt;left:341.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">metastasis count,</span></p>
<p style="top:641.5pt;left:344.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">cell maturation</span></p>
<p style="top:649.9pt;left:354.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">analysis,</span></p>
<p style="top:658.4pt;left:338.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">T-cell proliferation</span></p>
<p style="top:666.8pt;left:335.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">and e</span><span style="font-family:Rpxr,serif;font-size:6.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt">ector function</span></p>
<p style="top:603.6pt;left:410.0pt;line-height:6.8pt"><span style="font-family:URWPalladioL,serif;font-size:6.8pt">Ibrutinib inhibits tumor growth</span></p>
<p style="top:612.0pt;left:446.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">in vitro.</span></p>
<p style="top:620.4pt;left:409.8pt;line-height:6.8pt"><span style="font-family:URWPalladioL,serif;font-size:6.8pt">Treated mice su</span><span style="font-family:Rpxr,serif;font-size:6.8pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:6.8pt">er lower tumor</span></p>
<p style="top:628.8pt;left:415.6pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">burden and less metastases.</span></p>
<p style="top:637.3pt;left:413.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">MDSCs switch phenotype to</span></p>
<p style="top:645.7pt;left:412.2pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">mature dendritic cells in vitro</span></p>
<p style="top:654.2pt;left:410.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">and less MDSCs and more DCs</span></p>
<p style="top:662.6pt;left:446.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">in vivo.</span></p>
<p style="top:671.0pt;left:415.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Ibrutinib induces antitumor</span></p>
<p style="top:679.5pt;left:422.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Th1 and CTL response.</span></p>
<p style="top:691.7pt;left:97.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Legend: q2w: every 2 weeks; BTK: Bruton&#x2019;s tyrosine kinase; i.v.: intravenously; CTL: cytotoxic T lymphocytes;</span></p>
<p style="top:701.2pt;left:97.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">DC: dendritic cell; IC50: half maximal inhibitory concentration; MDSC: myeloid-derived suppressor cell; NSCLC:</span></p>
<p style="top:710.7pt;left:97.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">non-small-cell lung cancer; ORR: overall response rate; TNBC: triple-negative breast cancer.</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 4154</span></p>
<p style="top:56.6pt;left:495.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">6 of 17</span></p>
<p style="top:89.7pt;left:132.1pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Table 2.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Current evidence of the e</span><span style="font-family:Rpxr,serif;font-size:9.0pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">cacy of ibrutinib in gynecological malignancies.</span></p>
<p style="top:109.7pt;left:85.5pt;line-height:6.7pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.7pt">First Author</span></b></p>
<p style="top:118.0pt;left:95.7pt;line-height:6.7pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.7pt">[Ref.]</span></b></p>
<p style="top:113.9pt;left:144.9pt;line-height:6.7pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Year</span></b></p>
<p style="top:113.9pt;left:181.4pt;line-height:6.7pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Study Type</span></b></p>
<p style="top:113.9pt;left:247.1pt;line-height:6.7pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Model</span></b></p>
<p style="top:113.9pt;left:300.2pt;line-height:6.7pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Histology</span></b></p>
<p style="top:113.9pt;left:346.6pt;line-height:6.7pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Outcome Measures</span></b></p>
<p style="top:113.9pt;left:439.5pt;line-height:6.7pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Main Outcomes</span></b></p>
<p style="top:179.1pt;left:94.8pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Zucha</span></p>
<p style="top:179.1pt;left:144.9pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">2015</span></p>
<p style="top:175.0pt;left:182.0pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Pre-clinical:</span></p>
<p style="top:183.2pt;left:188.1pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">in vitro</span></p>
<p style="top:170.9pt;left:236.3pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Human tissue</span></p>
<p style="top:179.2pt;left:227.1pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">samples, cell culture,</span></p>
<p style="top:187.3pt;left:242.6pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">spheroids</span></p>
<p style="top:175.0pt;left:303.1pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Ovarian</span></p>
<p style="top:183.2pt;left:305.8pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">cancer</span></p>
<p style="top:175.0pt;left:357.0pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Cell viability,</span></p>
<p style="top:183.2pt;left:352.9pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">BTK expression</span></p>
<p style="top:129.8pt;left:417.9pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">BTK is a histological biomarker</span></p>
<p style="top:138.0pt;left:420.9pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">and a prognostic predictor of</span></p>
<p style="top:146.2pt;left:442.3pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">ovarian cancer.</span></p>
<p style="top:154.5pt;left:417.9pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Ovarian CSCs express BTK and</span></p>
<p style="top:162.7pt;left:445.0pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">contribute to</span></p>
<p style="top:170.9pt;left:435.8pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">cisplatin resistance.</span></p>
<p style="top:179.1pt;left:422.4pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">BTK inhibition targets CSCs</span></p>
<p style="top:187.3pt;left:425.2pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">and reduces their survival</span></p>
<p style="top:195.5pt;left:439.7pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">against cisplatin.</span></p>
<p style="top:203.8pt;left:435.9pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Cisplatin&#x2013;ibrutinib</span></p>
<p style="top:212.0pt;left:422.7pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">combination has synergistic</span></p>
<p style="top:220.2pt;left:420.9pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">e</span><span style="font-family:Rpxr,serif;font-size:6.7pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:6.7pt">ects in eliminating ovarian</span></p>
<p style="top:228.4pt;left:446.3pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">cancer cells.</span></p>
<p style="top:264.9pt;left:92.8pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Tamura</span></p>
<p style="top:264.9pt;left:144.9pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">2018</span></p>
<p style="top:260.8pt;left:183.1pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Preclinical:</span></p>
<p style="top:269.0pt;left:188.1pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">in vitro</span></p>
<p style="top:256.7pt;left:239.4pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Cell culture,</span></p>
<p style="top:264.9pt;left:233.9pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">patient-derived</span></p>
<p style="top:273.1pt;left:232.1pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">tumor organoids</span></p>
<p style="top:260.8pt;left:296.8pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Endometrial</span></p>
<p style="top:269.0pt;left:305.8pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">cancer</span></p>
<p style="top:256.7pt;left:359.3pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Tumor size,</span></p>
<p style="top:264.9pt;left:361.5pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">inhibitory</span></p>
<p style="top:273.1pt;left:355.9pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">concentration</span></p>
<p style="top:240.2pt;left:417.9pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Ibrutinib inhibits the growth of</span></p>
<p style="top:248.5pt;left:418.3pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">carboplatin</span><span style="font-family:Rpxr,serif;font-size:6.7pt">/</span><span style="font-family:URWPalladioL,serif;font-size:6.7pt">paclitaxel-resistant</span></p>
<p style="top:256.7pt;left:422.0pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">cells at lower concentrations</span></p>
<p style="top:264.9pt;left:423.3pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">than carboplatin, paclitaxel,</span></p>
<p style="top:273.1pt;left:421.6pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">methotrexate, and vindesine.</span></p>
<p style="top:281.3pt;left:427.7pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Less e</span><span style="font-family:Rpxr,serif;font-size:6.7pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:6.7pt">cacy in clear-cell</span></p>
<p style="top:289.6pt;left:425.0pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">adenocarcinoma cell lines.</span></p>
<p style="top:309.6pt;left:100.6pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Di</span></p>
<p style="top:309.6pt;left:144.9pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">2019</span></p>
<p style="top:305.5pt;left:183.1pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Preclinical:</span></p>
<p style="top:313.8pt;left:179.8pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">bioinformatics</span></p>
<p style="top:305.5pt;left:233.4pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Drug functional</span></p>
<p style="top:313.7pt;left:229.5pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">similarity network</span></p>
<p style="top:301.4pt;left:303.1pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Ovarian</span></p>
<p style="top:309.6pt;left:305.6pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">cancer,</span></p>
<p style="top:317.8pt;left:296.1pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">breast cancer</span></p>
<p style="top:305.5pt;left:351.7pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Prior score, false</span></p>
<p style="top:313.7pt;left:355.1pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">discovery rate</span></p>
<p style="top:305.5pt;left:423.4pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Low rank in ovarian cancer</span></p>
<p style="top:313.7pt;left:439.1pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">drug candidates.</span></p>
<p style="top:342.0pt;left:95.3pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Lohse</span></p>
<p style="top:342.0pt;left:144.9pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">2019</span></p>
<p style="top:337.9pt;left:183.1pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Preclinical:</span></p>
<p style="top:346.1pt;left:188.1pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">in vitro</span></p>
<p style="top:329.6pt;left:233.3pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Drug sensitivity</span></p>
<p style="top:337.9pt;left:243.3pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">testing in</span></p>
<p style="top:346.1pt;left:228.0pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">patient-derived cell</span></p>
<p style="top:354.3pt;left:250.2pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">lines</span></p>
<p style="top:337.9pt;left:303.1pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Ovarian</span></p>
<p style="top:346.1pt;left:305.8pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">cancer</span></p>
<p style="top:337.9pt;left:354.4pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Modi&#xfb01;ed drug</span></p>
<p style="top:346.1pt;left:349.2pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">sensitivity scoring</span></p>
<p style="top:329.6pt;left:421.4pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">Weak e</span><span style="font-family:Rpxr,serif;font-size:6.7pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:6.7pt">ect on endometrioid</span></p>
<p style="top:337.9pt;left:420.8pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">and papillary-serous cell line.</span></p>
<p style="top:346.1pt;left:432.1pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">No e</span><span style="font-family:Rpxr,serif;font-size:6.7pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:6.7pt">ect on clear-cell</span></p>
<p style="top:354.3pt;left:445.9pt;line-height:6.7pt"><span style="font-family:URWPalladioL,serif;font-size:6.7pt">cancer lines.</span></p>
<p style="top:366.3pt;left:186.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Legend: BTK: Bruton&#x2019;s tyrosine kinase; CSC: cancer stem cells.</span></p>
<p style="top:392.4pt;left:97.8pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Sti</span></b><span style="font-family:Rpxb,serif;font-size:10.0pt">&#xfb00;</span><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> et al</span></b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">. investigated the e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ect of ibrutinib on myeloid-derived suppressor cells (MDSCs) [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">35</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:405.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">In tumor-bearing hosts, these cells increased in response to factors released by tumors and stromal</span></p>
<p style="top:419.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">cells, and elevated expression subsequently a</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ected immune response and diminishes the e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">cacy</span></p>
<p style="top:432.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">of immunotherapy. In their work, they were able to document that human and murine MDSCs</span></p>
<p style="top:446.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">expressed BTK. Furthermore, ibrutinib inhibited the formation of human MDSCs</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vitro</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">. In the next</span></p>
<p style="top:460.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">experiment, ibrutinib was fed to mice with xenografted triple-negative mammary tumor cells. This led</span></p>
<p style="top:473.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">to a reduction in immune-suppressing MDSCs in the murine spleen and tumor. Lastly, a murine breast</span></p>
<p style="top:487.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">cancer model was used to assess the e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">cacy of a combined ibrutinib</span><span style="font-family:Rpxr,serif;font-size:9.9pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">anti-PD-L1 treatment, resulting in</span></p>
<p style="top:500.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">a signi&#xfb01;cant enhancement of the immunotherapies&#x2019; e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">cacy.</span></p>
<p style="top:513.9pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">After reporting that an isoform of BTK (BTK-C) protects breast cancer cells from apoptosis in</span></p>
<p style="top:527.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">2013 [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">36</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">], in 2016,</span><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> Wang et al.</span></b><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> showed that inhibition of BTK by ibrutinib could decrease cancer cell</span></p>
<p style="top:541.0pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">survival and prevent drug resistance [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">37</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. They found that HER2</span><sup><span style="font-family:Rpxr,serif;font-size:7.6pt">+</span></sup><sup><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> </span></sup><span style="font-family:URWPalladioL,serif;font-size:10.1pt">cell lines were more sensitive to</span></p>
<p style="top:554.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">drug treatment than luminal, triple-negative, or even nontumorigenic cell lines in cell growth assays.</span></p>
<p style="top:568.0pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">The e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ect of ibrutinib on monolayer and 3D culture was even more potent than that of lapatinib.</span></p>
<p style="top:581.6pt;left:76.1pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">As described earlier [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">33</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">], the phosphorylation of EGFR, HER2, Her3, and ErbB4 was inhibited, resulting</span></p>
<p style="top:595.2pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">in a blockage of activating downstream pathways. These e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ects were con&#xfb01;rmed</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vivo</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">, together with</span></p>
<p style="top:608.6pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">growth inhibition of the xenografted tumors in mice.</span></p>
<p style="top:622.1pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">The authors emphasized ibrutinib&#x2019;s dual e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ect on two key growth and survival kinases, namely,</span></p>
<p style="top:635.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">BTK and the EGFR family. This might explain its greater impact on HER2</span><sup><span style="font-family:Rpxr,serif;font-size:7.6pt">+</span></sup><sup><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> </span></sup><span style="font-family:URWPalladioL,serif;font-size:9.9pt">cells and provide a strong</span></p>
<p style="top:649.0pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">rationale for its clinical use, especially since a correlation between the expression of HER2 and BTK</span></p>
<p style="top:662.6pt;left:76.1pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">was found in human breast cancer tissue.</span></p>
<p style="top:676.0pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">As the development of new cancer drugs is slow and costly,</span><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> Di et al.</span></b><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">38</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">] generated a</span></p>
<p style="top:689.6pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">novel computational approach in order to determine candidate drugs that could possibly be</span></p>
<p style="top:703.1pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">repurposed to treat cancer.</span></p>
<p style="top:703.1pt;left:209.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">By using known drug-indication correlations and combining them</span></p>
<p style="top:716.7pt;left:76.1pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">with drug-drug and indication-indication similarities, they were subsequently able to hypothesize new</span></p>
<p style="top:730.2pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">drug-indication associations.</span></p>
<p style="top:743.7pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">The software used raw data from the National Cancer Institute (NCI)-60 cancer cell line database,</span></p>
<p style="top:757.1pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">a panel containing extensive data on the gene expression pro&#xfb01;les and pharmacology for 60 cancer</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 4154</span></p>
<p style="top:56.6pt;left:495.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">7 of 17</span></p>
<p style="top:89.8pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">cell lines, including breast and ovarian cancer.</span></p>
<p style="top:89.8pt;left:302.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">These data were used to study the correlation</span></p>
<p style="top:103.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">between mRNA</span><span style="font-family:Rpxr,serif;font-size:10.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">microRNA expression levels and drug susceptibility. They created a drug-drug</span></p>
<p style="top:116.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">functional similarity network in order to predict drug functional similarities at a biological pathway</span></p>
<p style="top:130.3pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">level. The system was validated using cross-validation tests on approved drugs, receiver-operating</span></p>
<p style="top:144.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">characteristic curve analysis, and literature searches, con&#xfb01;rming its e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ciency in prioritizing candidate</span></p>
<p style="top:157.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">cancer drugs.</span></p>
<p style="top:170.9pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Sixteen FDA approved drugs for the treatment of breast cancer were mapped to the described</span></p>
<p style="top:184.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">network. The algorithm then identi&#xfb01;ed 14 candidate drugs that were statistically signi&#xfb01;cant. In this list</span></p>
<p style="top:198.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">of prioritized scores, ibrutinib ranked 3rd out of more than 3000 substances tested and was &#x201c;considered</span></p>
<p style="top:211.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">to show great potential therapeutic e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ects&#x201d; [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">38</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Moreover, ranks 1 and 2 (ge&#xfb01;tinib and afatinib)</span></p>
<p style="top:225.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">represented two EGFR inhibitors, additional proof of the importance of this receptor in breast cancer</span></p>
<p style="top:238.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">treatment. After Sagiv-Bar&#xfb01; et al. showed a preclinical e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ect of ibrutinib and anti-PD-L1 antibodies</span></p>
<p style="top:251.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">in lymphoma, breast cancer, and colon cancer [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">34</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">],</span><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> Hong et al</span></b><span style="font-family:URWPalladioL,serif;font-size:10.1pt">. initiated an open-label, multicenter,</span></p>
<p style="top:265.4pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">phase Ib</span><span style="font-family:Rpxr,serif;font-size:10.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">II study evaluating ibrutinib plus durvalumab in humans [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">39</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Inclusion criteria included</span></p>
<p style="top:278.9pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">patients with stage III</span><span style="font-family:Rpxr,serif;font-size:10.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">IV breast cancer, pancreatic adenocarcinoma, and non-small-cell lung cancer</span></p>
<p style="top:292.6pt;left:76.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">(NSCLC). After de&#xfb01;ning a recommended phase 2 dose of 560 mg ibrutinib p.o. daily and durvalumab</span></p>
<p style="top:305.9pt;left:76.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">10 mg</span><span style="font-family:Rpxr,serif;font-size:10.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">kg intravenously (i.v.) twice a week in phase 1, they continued to treat 122 patients at that</span></p>
<p style="top:319.5pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">dose. Of these patients, 45 had breast cancer (28 TNBC, 17 HER2</span><sup><span style="font-family:Rpxr,serif;font-size:7.6pt">+</span></sup><span style="font-family:URWPalladioL,serif;font-size:10.1pt">), and all of them had previously</span></p>
<p style="top:333.0pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">been treated with</span><span style="font-family:Pxsy,serif;font-size:10.0pt"> &#x2265;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> 2 prior therapies. Ninety-four percent of the patients had stage IV disease at a</span></p>
<p style="top:346.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">median age of 61 years. An overall response rate of 3% was found in patients with breast cancer, with</span></p>
<p style="top:360.0pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">a median progression-free survival rate of 1.7 months. Pancreatic cancer and NSCLC ranged at an</span></p>
<p style="top:373.7pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">overall response rate of 2% and 0%, with a median progression-free survival rate of 1.7 and 2.0 months,</span></p>
<p style="top:387.0pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">respectively. While the safety pro&#xfb01;les of both drugs were consistent with previously known data</span></p>
<p style="top:400.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">and were considered acceptable, the antitumor activity in this pretreated, late-stage study population</span></p>
<p style="top:414.1pt;left:76.1pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">was limited.</span></p>
<p style="top:427.6pt;left:97.8pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Varikuti et al</span></b><span style="font-family:URWPalladioL,serif;font-size:9.9pt">. [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">40</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">] used an orthotopic mouse breast cancer model to investigate ibrutinib&#x2019;s e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ect</span></p>
<p style="top:441.0pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">on tumor progression and metastasis. Mice were injected with tumor cells resembling a luminal b</span></p>
<p style="top:454.6pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">subtype [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">41</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. After a growth period of one week, mice were randomized to treatment or placebo</span></p>
<p style="top:468.1pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">groups. Tumor progression, as well as tumor weight, were signi&#xfb01;cantly reduced in the treatment</span></p>
<p style="top:481.6pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">group. BTK expression in tumor tissue was decreased in a dose-dependent manner. Mice receiving</span></p>
<p style="top:495.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">the verum also had fewer lung metastases and splenomegaly when compared to the placebo group.</span></p>
<p style="top:508.6pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Immunosuppressive monocytic MDSCs were found to be reduced in the tumors and spleens of</span></p>
<p style="top:522.1pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">treated mice with an increase in mature dendritic cells (DCs). Furthermore, ibrutinib initiated a</span></p>
<p style="top:535.6pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">phenotype switch from MDSCs to DCs</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vitro</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">. Regarding immune response, the team was able to</span></p>
<p style="top:549.2pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">show that ibrutinib increased T cell e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ector functions, encouraged T cell proliferation, and promoted</span></p>
<p style="top:562.7pt;left:76.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Th1-dominant cytokines in vivo.</span></p>
<p style="top:576.2pt;left:97.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Table</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7"> 1</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> shows a summary of the studies described.</span></p>
<p style="top:599.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">2.2.2. Gynecological Malignancies</span></p>
<p style="top:618.9pt;left:97.8pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Zucha et al.</span></b><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">42</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">] studied BTK and its inhibition by ibrutinib comprehensively in human ovarian</span></p>
<p style="top:632.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">cancer tissue samples. They demonstrated a high expression of BTK in malignant cells with more</span></p>
<p style="top:645.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">intense staining in metastatic and late-stage disease.</span></p>
<p style="top:659.4pt;left:97.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">A further experiment demonstrated that cell lines highly resistant to platinum expressed higher</span></p>
<p style="top:672.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">levels of cancer stem cell (CSC) markers than cells with moderate or absent platinum resistance,</span></p>
<p style="top:686.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">indicating a higher fraction of CSCs in these cells.</span></p>
<p style="top:699.9pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Next, spheroids from the parental cell lines were generated, and the cisplatin responsiveness</span></p>
<p style="top:713.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">of spheroids and parental cell lines were compared. Spheroids of CSC-rich cell lines showed high</span></p>
<p style="top:727.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">resistance to platinum, indicating a major role of CSCs in cisplatin resistance, while BTK was critical in</span></p>
<p style="top:740.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">regulating ovarian CSCs.</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 4154</span></p>
<p style="top:56.6pt;left:495.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">8 of 17</span></p>
<p style="top:89.8pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">To prove the hypothesis that BTK mediates platinum resistance via regulation of CSCs,</span></p>
<p style="top:103.4pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">loss-of-function and gain-of-function studies were performed. In a primarily platinum-responsive cell</span></p>
<p style="top:116.9pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">line, the overexpression of BTK stimulated the activation of transcription factor STAT3. Consequently,</span></p>
<p style="top:130.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">several downstream e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ectors, known for their role in stem cell regulation and cell survival, such as SOX2</span></p>
<p style="top:144.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">and Bcl-xL, were upregulated. Following this &#x201c;stemness&#x201d; gene regulation, these cells formed spheroids</span></p>
<p style="top:157.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">and increased their CSC count. In contrast, JAK2</span><span style="font-family:Rpxr,serif;font-size:9.9pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">STAT3 targets (such as Bcl-xL) were downregulated in</span></p>
<p style="top:171.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">BTK knockdown loss-of-function studies. Treatment with ibrutinib showed a similar e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ect, decreasing</span></p>
<p style="top:184.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">BTK phosphorylation and Sox2</span><span style="font-family:Rpxr,serif;font-size:10.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Bcl-xL expression. This diminished the self-renewal capacities of</span></p>
<p style="top:198.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">highly malignant cells and their proportion of CSCs, which ultimately reduced the population and its</span></p>
<p style="top:211.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">spheroid-forming abilities. Cell lines initially highly resistant to cisplatin became more sensitive after</span></p>
<p style="top:224.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">BTK knockdown. A synergistic e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ect of ibrutinib and cisplatin was shown in serous and clear cell</span></p>
<p style="top:238.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">lines, indicating the possible use of ibrutinib as a platinum sensitizer in these malignancies.</span></p>
<p style="top:251.9pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">There also is evidence for an antiproliferative role of ibrutinib in endometrial cancer.</span></p>
<p style="top:265.5pt;left:76.2pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Tamura et al</span></b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">. [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">43</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">] created patient-derived tumor organoids (PDOs) from human tumor tissue (lung,</span></p>
<p style="top:278.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ovarian, endometrial). The morphology, histology, and gene expression of these organoids were</span></p>
<p style="top:292.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">similar to their source tumor. The reaction to a total of 61 anticancer agents was tested in cell growth</span></p>
<p style="top:305.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">inhibition experiments. Subsequently, the e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">cacy of each anticancer agent was evaluated. A PDO</span></p>
<p style="top:319.5pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">called REME9 was derived from carboplatin</span><span style="font-family:Rpxr,serif;font-size:10.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">paclitaxel-resistant endometrial cancer. As expected,</span></p>
<p style="top:333.0pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">carboplatin and paclitaxel showed only weak e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ects on this cell line, an observation that suggested</span></p>
<p style="top:346.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">certain comparability between the PDOs and the source tumor regarding the drug response. Ibrutinib</span></p>
<p style="top:360.0pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">led to growth inhibition in these cells at concentrations (AUC) notably lower than carboplatin and</span></p>
<p style="top:373.7pt;left:76.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">paclitaxel, but also lower than MTX and vinca alkaloids&#x2014;substances that current guidelines recommend</span></p>
<p style="top:387.0pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">as a possible treatment for metastatic patients. However, ibrutinib had much less e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ect in clear-cell</span></p>
<p style="top:400.6pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">adenocarcinoma specimens. A comparison with the e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ect of anthracyclines was not possible, as this</span></p>
<p style="top:414.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">substance class was not investigated.</span></p>
<p style="top:427.7pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">The drug-drug functional similarity network created by</span><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> Di et al.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">38</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">] has been described in detail</span></p>
<p style="top:441.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in in Section</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7"> 2.2.1</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> above. Even though ibrutinib achieved a high score as a potential agent for breast</span></p>
<p style="top:454.7pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">cancer treatment, it failed to thrive in the experiments on ovarian cancer and ranged in the last sextile</span></p>
<p style="top:468.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">of the candidate drug list ranking.</span></p>
<p style="top:481.7pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">As treatment options in platinum-resistant ovarian cancer are scarce,</span><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> Lohse et al.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">44</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">] investigated</span></p>
<p style="top:495.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">the treatment response to 30 FDA-approved chemotherapeutics in six such patient-derived cell lines,</span></p>
<p style="top:508.6pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">using ex vivo drug sensitivity testing. The experiments were performed on two endometrioid, two</span></p>
<p style="top:522.1pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">clear-cell, and two papillary-serous cell lines, respectively. To interpret and compare the di</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">erent</span></p>
<p style="top:535.8pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">drugs, the modi&#xfb01;ed drug sensitivity score was used, a marker incorporating di</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">erent parameters, such</span></p>
<p style="top:549.3pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">as potency, e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">cacy, e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ect range, and therapeutic index, allowing for prioritization of compounds with</span></p>
<p style="top:562.8pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">one sole numerical metric. In light of this</span><i><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> personalized medicine</span></i><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> approach, di</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ering treatment responses</span></p>
<p style="top:576.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">between cell lines were observed. While docetaxel and cephalomannine diminished the survival of</span></p>
<p style="top:589.6pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">all cell lines tested, the e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ect of ibrutinib varied greatly. A weak inhibitory e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ect was found on one</span></p>
<p style="top:603.3pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">endometrioid and papillary-serous cell line, respectively, while no e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ect was seen on clear-cell cancer</span></p>
<p style="top:616.7pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">lines. Ibrutinib generally provoked less treatment response compared to the tested antimitotics, such</span></p>
<p style="top:630.2pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">as docetaxel. The response to each drug varied greatly and was partly unpredictable between the</span></p>
<p style="top:643.8pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">cell lines tested. Afatinib, for example, another kinase inhibitor tested, was the top candidate against</span></p>
<p style="top:657.2pt;left:76.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">papillary-serous cell line P5X but showed the poorest speci&#xfb01;city against the second papillary-serous</span></p>
<p style="top:670.8pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">cell line P9A1.</span></p>
<p style="top:684.3pt;left:97.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Table</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7"> 2</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> shows a summary of the studies investigating ibrutinib in gynecological malignancies.</span></p>
<p style="top:707.5pt;left:76.5pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">2.3. Clinical Trials</span></i></p>
<p style="top:727.1pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Three trials investigating ibrutinib&#x2019;s use in gynecological malignancies were identi&#xfb01;ed. Figure</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt;color:#0774b7"> A1</span></p>
<p style="top:740.5pt;left:76.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">(Appendix</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7"> A</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">) shows the &#xfb02;ow diagram for the identi&#xfb01;cation of relevant trials.</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 4154</span></p>
<p style="top:56.6pt;left:495.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">9 of 17</span></p>
<p style="top:89.9pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">NCT02403271 is a phase Ib</span><span style="font-family:Rpxr,serif;font-size:9.9pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">II trial, assessing the safety and e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">cacy of a combination of ibrutinib</span></p>
<p style="top:103.5pt;left:76.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">(560 mg daily) and durvalumab in patients with relapsed or refractory solid tumors. As the results have</span></p>
<p style="top:117.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">already been published by Hong et al. [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">39</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">], please refer to the &#x201c;Results&#x201d; section above for further details.</span></p>
<p style="top:130.5pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">NCT03379428, &#x201c;Trial of Ibrutinib Plus Trastuzumab in Her2-Ampli&#xfb01;ed Metastatic Breast Cancer&#x201d;,</span></p>
<p style="top:144.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">is a phase I</span><span style="font-family:Rpxr,serif;font-size:9.9pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">II, open-label, nonrandomized dose-escalation study. Its primary objectives are to de&#xfb01;ne a</span></p>
<p style="top:157.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">maximum tolerated dose of oral ibrutinib (420, 560 or 840 mg, phase I) and to assess the clinical bene&#xfb01;t</span></p>
<p style="top:171.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">rate (phase II) in patients with HER2</span><sup><span style="font-family:Rpxr,serif;font-size:7.6pt">+</span></sup><sup><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> </span></sup><span style="font-family:URWPalladioL,serif;font-size:9.9pt">metastatic breast cancer. At the same time, the patients receive</span></p>
<p style="top:184.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">3-weekly trastuzumab intravenously. With the rationale of continuing a dual HER2 blockade after</span></p>
<p style="top:197.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">the failure of second-line therapy, the inclusion is limited to patients with disease progression after</span></p>
<p style="top:211.5pt;left:76.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">prior T-DM1. As of May 2020, the trial is active and recruiting, with estimated primary completion in</span></p>
<p style="top:225.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">December 2020.</span></p>
<p style="top:238.5pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">NCT03525925, &#x201c;Ibrutinib and Nivolumab in Treating Participants with Metastatic Solid Tumors&#x201d;,</span></p>
<p style="top:251.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">is a phase I trial investigating the e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ect of ibrutinib and nivolumab on myeloid-derived suppressor</span></p>
<p style="top:265.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">cells. Patients with metastatic solid neoplasms and any number of prior lines of therapy are eligible</span></p>
<p style="top:278.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">for inclusion. Patients receive oral ibrutinib (420 mg daily) for 15 days and intravenous nivolumab</span></p>
<p style="top:292.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">on days 8 and 21 with subsequent repeated courses of nivolumab every 28 days until disease</span></p>
<p style="top:305.9pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">progression or unaccepted toxicity. The primary objective is to evaluate the levels of circulating</span></p>
<p style="top:319.5pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">MDSCs, with a secondary objective being the assessment of the safety of the study combination.</span></p>
<p style="top:333.0pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">The immunosuppressive potency of MDSCs is measured by their T cell inhibition ability and by</span></p>
<p style="top:346.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">examining antibody-dependent cell toxicity mediated by natural killer cells. The study is active but</span></p>
<p style="top:360.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">not recruiting, with estimated primary completion in September 2020.</span></p>
<p style="top:373.6pt;left:97.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">In Table</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7"> 3</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">, we summarized the clinical trials described.</span></p>
<p style="top:398.0pt;left:97.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Table 3.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Clinical trials investigating the use of ibrutinib in gynecological malignancies, including</span></p>
<p style="top:410.8pt;left:97.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">breast cancer.</span></p>
<p style="top:430.6pt;left:117.6pt;line-height:6.3pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.3pt">Ref.</span></b></p>
<p style="top:430.6pt;left:191.3pt;line-height:6.3pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.3pt">Title</span></b></p>
<p style="top:430.6pt;left:278.7pt;line-height:6.3pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.3pt">Phase</span></b><span style="font-family:Rpxb,serif;font-size:6.3pt">/</span><b><span style="font-family:URWPalladioL,serif;font-size:6.3pt"> Status</span></b></p>
<p style="top:430.6pt;left:375.5pt;line-height:6.3pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.3pt">Brief Summary</span></b></p>
<p style="top:430.6pt;left:445.1pt;line-height:6.3pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.3pt">Primary Outcomes</span></b></p>
<p style="top:464.7pt;left:98.1pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">NCT02403271 [</span><span style="font-family:URWPalladioL,serif;font-size:6.3pt;color:#0774b7">15</span><span style="font-family:URWPalladioL,serif;font-size:6.3pt">]</span></p>
<p style="top:445.5pt;left:164.1pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">A Multi-Center Study of</span></p>
<p style="top:453.2pt;left:163.1pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">Ibrutinib in Combination</span></p>
<p style="top:460.9pt;left:176.0pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">with MEDI4736</span></p>
<p style="top:468.5pt;left:162.5pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">[Durvalumab] in Subjects</span></p>
<p style="top:476.2pt;left:158.6pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">With Relapsed or Refractory</span></p>
<p style="top:483.9pt;left:179.5pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">Solid Tumors</span></p>
<p style="top:457.0pt;left:282.5pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">Phase Ib</span><span style="font-family:Rpxr,serif;font-size:6.3pt">/</span><span style="font-family:URWPalladioL,serif;font-size:6.3pt">II;</span></p>
<p style="top:464.7pt;left:250.7pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">completed</span><span style="font-family:URWPalladioL,serif;font-size:4.9pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:4.9pt">1</span></sup><sup><span style="font-family:URWPalladioL,serif;font-size:6.3pt"> </span></sup><span style="font-family:URWPalladioL,serif;font-size:6.3pt">(Ref.: Results section,</span></p>
<p style="top:472.4pt;left:267.5pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">Hong et al., 2019 [</span><span style="font-family:URWPalladioL,serif;font-size:6.3pt;color:#0774b7">41</span><span style="font-family:URWPalladioL,serif;font-size:6.3pt">])</span></p>
<p style="top:441.7pt;left:360.9pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">A phase 1b</span><span style="font-family:Rpxr,serif;font-size:6.3pt">/</span><span style="font-family:URWPalladioL,serif;font-size:6.3pt">2, multi-center</span></p>
<p style="top:449.4pt;left:362.7pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">study to assess the safety</span></p>
<p style="top:457.0pt;left:360.7pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">and e</span><span style="font-family:Rpxr,serif;font-size:6.3pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:6.3pt">cacy of ibrutinib in</span></p>
<p style="top:464.7pt;left:372.8pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">combination with</span></p>
<p style="top:472.4pt;left:359.0pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">durvalumab (MEDI4736) in</span></p>
<p style="top:480.1pt;left:357.8pt;line-height:6.2pt"><span style="font-family:URWPalladioL,serif;font-size:6.2pt">participants with relapsed or</span></p>
<p style="top:487.7pt;left:364.6pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">refractory solid tumors.</span></p>
<p style="top:449.4pt;left:457.2pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">Safety and</span></p>
<p style="top:457.0pt;left:456.6pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">tolerability,</span></p>
<p style="top:464.7pt;left:461.7pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">dosage,</span></p>
<p style="top:472.4pt;left:449.2pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">overall response</span></p>
<p style="top:480.1pt;left:445.1pt;line-height:6.2pt"><span style="font-family:URWPalladioL,serif;font-size:6.2pt">rate per RECIST 1.1</span></p>
<p style="top:540.9pt;left:98.1pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">NCT03379428 [</span><span style="font-family:URWPalladioL,serif;font-size:6.3pt;color:#0774b7">16</span><span style="font-family:URWPalladioL,serif;font-size:6.3pt">]</span></p>
<p style="top:529.4pt;left:168.2pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">Trial of Ibrutinib Plus</span></p>
<p style="top:537.1pt;left:176.1pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">Trastuzumab in</span></p>
<p style="top:544.8pt;left:159.3pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">HER2-Ampli&#xfb01;ed Metastatic</span></p>
<p style="top:552.4pt;left:178.9pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">Breast Cancer</span></p>
<p style="top:537.1pt;left:284.3pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">Phase I</span><span style="font-family:Rpxr,serif;font-size:6.3pt">/</span><span style="font-family:URWPalladioL,serif;font-size:6.3pt">II;</span></p>
<p style="top:544.8pt;left:281.9pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">recruiting</span><span style="font-family:URWPalladioL,serif;font-size:4.9pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:4.9pt">1</span></sup></p>
<p style="top:498.7pt;left:359.9pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">Open-label dose-escalation</span></p>
<p style="top:506.4pt;left:368.3pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">study to evaluate the</span></p>
<p style="top:514.1pt;left:362.3pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">maximum-tolerated dose</span></p>
<p style="top:521.8pt;left:366.3pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">and dose-limiting side</span></p>
<p style="top:529.4pt;left:358.1pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">e</span><span style="font-family:Rpxr,serif;font-size:6.3pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:6.3pt">ects of daily oral ibrutinib</span></p>
<p style="top:537.1pt;left:369.3pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">in combination with</span></p>
<p style="top:544.8pt;left:367.9pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">trastuzumab i.v. q3w,</span></p>
<p style="top:552.4pt;left:375.6pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">in patients with</span></p>
<p style="top:560.1pt;left:359.8pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">HER2-ampli&#xfb01;ed metastatic</span></p>
<p style="top:567.8pt;left:359.5pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">breast cancer with progress</span></p>
<p style="top:575.5pt;left:371.7pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">after prior therapy</span></p>
<p style="top:583.1pt;left:379.5pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">with T-DM1.</span></p>
<p style="top:533.3pt;left:445.1pt;line-height:6.2pt"><span style="font-family:URWPalladioL,serif;font-size:6.2pt">Maximum-tolerated</span></p>
<p style="top:540.9pt;left:465.0pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">dose,</span></p>
<p style="top:548.6pt;left:445.6pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">clinical bene&#xfb01;t rate</span></p>
<p style="top:617.2pt;left:98.1pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">NCT03525925 [</span><span style="font-family:URWPalladioL,serif;font-size:6.3pt;color:#0774b7">17</span><span style="font-family:URWPalladioL,serif;font-size:6.3pt">]</span></p>
<p style="top:609.5pt;left:159.3pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">Ibrutinib and Nivolumab in</span></p>
<p style="top:617.2pt;left:161.9pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">Treating Participants with</span></p>
<p style="top:624.8pt;left:164.4pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">Metastatic Solid Tumors</span></p>
<p style="top:613.3pt;left:287.3pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">Phase I;</span></p>
<p style="top:621.0pt;left:266.8pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">active, not recruiting</span><span style="font-family:URWPalladioL,serif;font-size:4.9pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:4.9pt">1</span></sup></p>
<p style="top:594.2pt;left:358.8pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">A phase I trial investigating</span></p>
<p style="top:601.8pt;left:362.3pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">the e</span><span style="font-family:Rpxr,serif;font-size:6.3pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:6.3pt">ect of ibrutinib and</span></p>
<p style="top:609.5pt;left:362.4pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">nivolumab on circulating</span></p>
<p style="top:617.2pt;left:359.1pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">levels of MDSCs in patients</span></p>
<p style="top:624.8pt;left:357.7pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">with metastatic solid tumors</span></p>
<p style="top:632.5pt;left:360.7pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">and assessing the safety of</span></p>
<p style="top:640.2pt;left:365.3pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">the study combination.</span></p>
<p style="top:609.5pt;left:447.5pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">Circulating levels</span></p>
<p style="top:617.2pt;left:445.1pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">of myeloid-derived</span></p>
<p style="top:624.8pt;left:449.7pt;line-height:6.3pt"><span style="font-family:URWPalladioL,serif;font-size:6.3pt">suppressor cells</span></p>
<p style="top:650.3pt;left:228.6pt;line-height:6.0pt"><span style="font-family:URWPalladioL,serif;font-size:6.0pt">1</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> Recruiting status as of May 1st, 2020.</span></p>
<p style="top:681.4pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3. Discussion</span></b></p>
<p style="top:701.0pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Ibrutinib has surpassed its initial indication for hematological malignancies and is about to acquire</span></p>
<p style="top:714.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">an increasing</span><i><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> raison d&#x2019;</span></i><i><span style="font-family:VnURWPalladioL,serif;font-size:10.0pt">&#xea;</span></i><i><span style="font-family:URWPalladioL,serif;font-size:9.9pt">tre</span></i><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> in gynecological malignancies and breast cancer. It has become clear that the</span></p>
<p style="top:727.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">mode of action extends beyond B cells, as the compound a</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ects signaling pathways downstream of</span></p>
<p style="top:741.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">multiple other receptors [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">4</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">8</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Its promising e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">cacy on solid tumors can be explained by di</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">erent</span></p>
<p style="top:754.8pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">means. As di</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">erent tumor types rely on heterogeneous intracellular pathways and greatly vary in</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 4154</span></p>
<p style="top:56.6pt;left:491.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">10 of 17</span></p>
<p style="top:89.8pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">driver mutations, gene expression, and protein endowment, it is important to note that ibrutinib&#x2019;s</span></p>
<p style="top:103.5pt;left:76.5pt;line-height:9.9pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.9pt">modus operandi</span></i><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> in one tumor cannot be transferred to another. The mechanisms described below consist</span></p>
<p style="top:116.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">of complex interactions between the drug, the tumor, and its microenvironment.</span></p>
<p style="top:130.3pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">First, ibrutinib shows on-target BTK inhibition in certain solid tumors. Ovarian cancer cells</span></p>
<p style="top:143.8pt;left:76.1pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">were found to express BTK, correlating with higher clinical disease stage, the risk for metastasis,</span></p>
<p style="top:157.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and survival [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">42</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. This could be used as both a prognostic predictor and a pharmacological target.</span></p>
<p style="top:170.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Furthermore, Zucha et al. showed that ibrutinib diminished the self-renewal capacities and the</span></p>
<p style="top:184.4pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">proportion of CSCs in ovarian cancer due to their BTK dependence. Cisplatin resistance of CSCs</span></p>
<p style="top:198.0pt;left:76.1pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">was surmounted, promoting a synergistic e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ect of both drugs [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">42</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. While the calculations performed</span></p>
<p style="top:211.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">by Di et al. implied no use as an ovarian cancer drug candidate [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">21</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], their results were purely</span></p>
<p style="top:224.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">computational and were never con&#xfb01;rmed by testing.</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> In vitro</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> testing performed by Lohse et al.,</span></p>
<p style="top:238.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">however, did show a weak e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ect on certain cell lines. Further on-target e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ects were identi&#xfb01;ed by</span></p>
<p style="top:252.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Eifert et al. [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">36</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">] and Wang et al. [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">37</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. BTK-C, an isoform of BTK, was expressed in 30% of breast cancer</span></p>
<p style="top:265.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">tissue, with an even higher percentage (43%) in HER2</span><sup><span style="font-family:Rpxr,serif;font-size:7.6pt">+</span></sup><sup><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> </span></sup><span style="font-family:URWPalladioL,serif;font-size:9.9pt">tumors. The observed reduction of HER2</span><sup><span style="font-family:Rpxr,serif;font-size:7.6pt">+</span></sup><sup><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> </span></sup><span style="font-family:URWPalladioL,serif;font-size:9.9pt">cell</span></p>
<p style="top:279.0pt;left:76.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">viability is proposed to be mediated via BTK&#x2019;s role in the AKT-ERK axis. A synergistic e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ect between</span></p>
<p style="top:292.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">direct inhibition of BTK (-C) and HER2 (as described below) is likely.</span></p>
<p style="top:305.9pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Second, the e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ects of ibrutinib in- and outside the TEC family kinases, which are linked to the</span></p>
<p style="top:319.5pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">inhibition of certain additional proteins, do exist. In BTK, ibrutinib covalently binds to a cysteine</span></p>
<p style="top:333.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">residue in the ATP-binding domain. Several other enzymes contain homologous cysteine residues at</span></p>
<p style="top:346.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">analogous positions, as it is conserved among at least nine other tyrosine kinases [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">2</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. An e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ect has been</span></p>
<p style="top:360.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">described for ERBB family kinases (EGFR, HER2, HER3, HER4), TEC family kinases (TEC, BTK, BMX,</span></p>
<p style="top:373.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ITK, RLK), and others (JAK3, BLK, FGR, HCK, LCK, Yes</span><span style="font-family:Rpxr,serif;font-size:9.9pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">YES1) [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">8</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">45</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Even at low concentrations of 1</span></p>
<p style="top:387.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:EURM10,serif;font-size:10.0pt">&#xb5;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">mol</span><span style="font-family:Rpxr,serif;font-size:10.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">L, ibrutinib is able to inhibit 16 kinases by</span><span style="font-family:Rpxr,serif;font-size:10.0pt"> &gt;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> 95% [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">46</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:400.6pt;left:97.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Changes in the expression or structure of tyrosine kinase receptors are known to be common in</span></p>
<p style="top:414.2pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">di</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">erent human cancers and allow for pharmaceutical targeting. Ibrutinib rapidly binds to these targets,</span></p>
<p style="top:427.5pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">leading to reduced phosphorylation of kinases, such as ErbB1-3 [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">33</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. This inhibition is irreversible,</span></p>
<p style="top:441.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">allowing for its typical once to twice daily dosage despite a short plasma half-life [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">2</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:454.7pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">The inhibitory e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ect on EGFR has been speci&#xfb01;cally explored and is e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ective in di</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">erent tumor cell</span></p>
<p style="top:468.2pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">lines, such as EGFR-mutant non-small-cell lung cancer (NSCLC) in mice [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">7</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Screening of large panels</span></p>
<p style="top:481.7pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">of cell lines has proved that ibrutinib suppresses the growth of cells suppressed by other EGFR</span><span style="font-family:Rpxr,serif;font-size:9.9pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">HER2</span></p>
<p style="top:495.2pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">inhibitors [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">2</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Chen et al. did not &#xfb01;nd an e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ect of ibrutinib on HER2-negative cell lines during several</span></p>
<p style="top:508.6pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">broad screenings [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">2</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], a &#xfb01;nding that strengthens the hypothesis of ERBB family blocking as a main</span></p>
<p style="top:522.2pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">mode of action.</span></p>
<p style="top:535.6pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">The e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ect on the ERBB family, and especially HER2, becomes even more relevant as HER2</span></p>
<p style="top:549.2pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">overexpression occurs in approximately 20% of breast cancers, resulting in more aggressive subtypes.</span></p>
<p style="top:562.7pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">In mice xenografted with HER2</span><sup><span style="font-family:Rpxr,serif;font-size:7.6pt">+</span></sup><sup><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> </span></sup><span style="font-family:URWPalladioL,serif;font-size:10.0pt">cells, a signi&#xfb01;cant tumor growth inhibition was seen at nanomolar,</span></p>
<p style="top:576.2pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">clinically achievable concentrations, and is an encouraging result [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">2</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">33</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:589.7pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">While antibodies targeting HER2 have made their way into everyday clinical practice since long,</span></p>
<p style="top:603.2pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">experiments in breast cancer cell lines have revealed ibrutinib to be a promising small-molecule</span></p>
<p style="top:616.8pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">addition to the arsenal. As it is most potent in HER2-overexpressing cell lines, these seem to be among</span></p>
<p style="top:630.3pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">the most promising candidates for possible future ibrutinib treatment, especially when considering the</span></p>
<p style="top:643.8pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">synergies described further above. This emphasizes the drug&#x2019;s multifunctional ability to exert di</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">erent</span></p>
<p style="top:657.2pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">antineoplastic mechanisms, as outlined earlier. Combining these multiple e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ects with additional</span></p>
<p style="top:670.9pt;left:76.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">pharmaceutical drugs, such as trastuzumab, is an auspicious approach and is currently being explored</span></p>
<p style="top:684.4pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">in a clinical trial [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">16</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Ibrutinib&#x2019;s inhibition of bone marrow X-linked kinase (BMX) is another promising</span></p>
<p style="top:697.9pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">target but remains largely unexplored in gynecological tumors and breast cancer. BMX is overexpressed</span></p>
<p style="top:711.3pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in several tumor types and promotes cell proliferation through the PI3K</span><span style="font-family:Rpxr,serif;font-size:10.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">AKT pathway. Its blockage</span></p>
<p style="top:724.9pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">could be of interest, especially when combined with PI3K</span><span style="font-family:Rpxr,serif;font-size:9.9pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">AKT inhibitors [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">4</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. It has been shown to be</span></p>
<p style="top:738.3pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">up-regulated in breast and cervical cancer, enhancing cell proliferation, invasiveness, and migration.</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 4154</span></p>
<p style="top:56.6pt;left:491.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">11 of 17</span></p>
<p style="top:89.8pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">BMX expression correlates with tumor di</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">erentiation and TNM stage [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">47</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">48</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">] and is able to increase</span></p>
<p style="top:103.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">apoptotic resistance to chemotherapeutic drugs [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">49</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:116.9pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Third, immunomodulation relating to MDSC&#x2019;s and PD-(L)1 seems to play a key role when using</span></p>
<p style="top:130.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ibrutinib alone or in combination with other therapeutics. MDSCs, which are present in the stroma</span></p>
<p style="top:143.8pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">of many di</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">erent tumors, have been shown to cause evasion of antitumor immune responses by</span></p>
<p style="top:157.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">immunosuppression and to reduce the e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">cacy of immune therapy [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">3</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">8</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. As they express BTK [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">35</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">],</span></p>
<p style="top:171.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">the corresponding inhibitors may reduce MDSCs</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vivo</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">. Additionally, ibrutinib diminishes cytokine</span></p>
<p style="top:184.4pt;left:76.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">production, PD-L1 expression, and motility of MDSCs and other myeloid cells, which consequently</span></p>
<p style="top:197.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">a</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ects tumor microenvironment regulation and has been linked to decreased tumor vasculature</span></p>
<p style="top:211.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">density [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">4</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. In the murine model of Sti</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> et al., treatment with ibrutinib resulted in a reduced frequency</span></p>
<p style="top:225.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">of MDSCs in mammary tumors and signi&#xfb01;cantly improved the e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">cacy of anti-PD-L1 therapy in breast</span></p>
<p style="top:238.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">cancer, possibly providing a novel strategy for enhancing immune therapies in solid malignancies [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">35</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">].</span></p>
<p style="top:252.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Ibrutinib&#x2019;s in&#xfb02;uence on circulating MDSCs and its synergistic e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ect with anti-PD1 targeted therapy are</span></p>
<p style="top:265.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">currently under investigation in humans. We highly anticipate the results of NCT03525925 [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">17</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">] in order</span></p>
<p style="top:278.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">to improve our knowledge about the e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ects of this promising combination. The observed synergy</span></p>
<p style="top:292.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">of ibrutinib and immune checkpoint inhibition is in line with the work of Sagiv-Bar&#xfb01; et al., where</span></p>
<p style="top:305.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">the combination of ibrutinib with anti-PD-L1 agents proved e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">cient even in tumors (lymphomas)</span></p>
<p style="top:319.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">intrinsically insensitive to ibrutinib, with an approx. 50% cure rate in mice. In their breast cancer model,</span></p>
<p style="top:333.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">a similar e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ect was found despite BTK negativity and low PD-L1 expression. Hypothesizing that the</span></p>
<p style="top:346.5pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">synergistic e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ect of ibrutinib augments the e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ectiveness of the PD1</span><span style="font-family:Rpxr,serif;font-size:10.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">PD-L1 blockade by increasing</span></p>
<p style="top:360.0pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">antitumor T cell response [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">3</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], these data suggest a novel role of the compound as a booster of T cell</span></p>
<p style="top:373.6pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">therapies. An increase of CD4</span><sup><span style="font-family:Rpxr,serif;font-size:7.6pt">+</span></sup><sup><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> </span></sup><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Th1</span><span style="font-family:Rpxr,serif;font-size:10.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Th2 cells and tumor-speci&#xfb01;c antigen expression by CD8</span><sup><span style="font-family:Rpxr,serif;font-size:7.6pt">+</span></sup><sup><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> </span></sup><span style="font-family:URWPalladioL,serif;font-size:10.0pt">T cells</span></p>
<p style="top:387.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">has been outlined on a molecular basis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">4</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">], as elaborated in the next paragraph.</span></p>
<p style="top:400.5pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Fourth, antineoplastic e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ects can be explained by further modulation of adaptive immunity.</span></p>
<p style="top:414.0pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">One mechanism of tumor immune escape is to induce a Th2-dominant helper T cell response with</span></p>
<p style="top:427.7pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">antibody production instead of a Th1-dominant response. However, ibrutinib causes a shift towards the</span></p>
<p style="top:441.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">favorable Th1-based immune response and cell-mediated cytotoxicity [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">45</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">50</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">51</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">], leading to increased</span></p>
<p style="top:454.6pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">maturation of cytotoxic T cells and depletion of immunosuppressive cytokines, such as IL-10 and</span></p>
<p style="top:468.1pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">TGF-</span><span style="font-family:EURM10,serif;font-size:10.0pt">&#x3b2;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">3</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. This e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ect is mediated by inhibiting interleukin-2-inducible T cell kinase (ITK), a TEC</span></p>
<p style="top:481.7pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">kinase that modulates the development and function of T cell immune response [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">34</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">45</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">], whereas Th1</span></p>
<p style="top:495.2pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">and CD8</span><sup><span style="font-family:Rpxr,serif;font-size:7.6pt">+</span></sup><sup><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> </span></sup><span style="font-family:URWPalladioL,serif;font-size:10.0pt">cells can rely on an escape route for maturation [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">4</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:508.6pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Ibrutinib&#x2019;s performance varied greatly between animal and human studies in the trials</span></p>
<p style="top:522.1pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">described [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">39</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">40</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. These contrasting results are multicausal. As with every experimental model,</span></p>
<p style="top:535.6pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">it is challenging to transfer the results to humans, adding numerous layers of complexity to a cell</span></p>
<p style="top:549.2pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">line or animal model. Even highly promising preclinical results had to be abandoned upon failing to</span></p>
<p style="top:562.6pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">show results in human trials. Nevertheless, the proposed mechanisms of action have been studied</span></p>
<p style="top:576.1pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">in-depth and sound plausible. The limited data available on human use are insu</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">cient to render a</span></p>
<p style="top:589.6pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">complete picture of the drug&#x2019;s capabilities, even more so, as the study population in the phase 1b</span><span style="font-family:Rpxr,serif;font-size:10.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">2</span></p>
<p style="top:603.3pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">trial is heavily pretreated and su</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ers end-stage disease, which inevitably leads to short life expectancy</span></p>
<p style="top:616.7pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">and high drop-out quotas. In future research, clear inclusion criteria, ex vivo sensitivity, and genetic</span></p>
<p style="top:630.2pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">testing will be crucial in order to select prime candidates. With the optimal patient selection, we are</span></p>
<p style="top:643.8pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">optimistic that the encouraging preclinical results can be transferred to a broader clinical appliance.</span></p>
<p style="top:657.2pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">As the paradigm in oncology has shifted from mere inhibition of cell division to a more</span></p>
<p style="top:670.7pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">holistic approach investigating the tumor and its environment, ibrutinib, with its inhibitory and</span></p>
<p style="top:684.4pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">immunomodulating e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ects, takes up an intriguing role. Future research should clearly focus on its use</span></p>
<p style="top:697.9pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">in HER2</span><sup><span style="font-family:Rpxr,serif;font-size:7.6pt">+</span></sup><sup><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> </span></sup><span style="font-family:URWPalladioL,serif;font-size:9.9pt">tumors as well as its possibilities as an enhancer of chemo- and immune therapy. In the near</span></p>
<p style="top:711.4pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">future, the results of the ongoing trials NCT03379428 and NCT03525925 could add further evidence in</span></p>
<p style="top:724.8pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">respect thereof.</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 4154</span></p>
<p style="top:56.6pt;left:491.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">12 of 17</span></p>
<p style="top:89.9pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">4. Materials and Methods</span></b></p>
<p style="top:113.1pt;left:76.5pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">4.1. Inclusion Criteria</span></i></p>
<p style="top:132.5pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">For this review, studies were considered eligible if they covered (at least in one aspect) the</span></p>
<p style="top:146.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">investigation or use of ibrutinib in gynecological malignancies (including breast cancer) in theoretical</span></p>
<p style="top:159.6pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">or empirical (human, animal, or</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vitro</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">) studies. As per protocol, fundamental research, preclinical,</span></p>
<p style="top:173.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">and clinical studies in English published until April 1, 2020, were considered for this review. We did</span></p>
<p style="top:186.7pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">not include reviews, conference abstracts, or notes without an abstract. No other restrictions were used.</span></p>
<p style="top:200.1pt;left:97.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Clinical trials were considered eligible if they investigated the use of ibrutinib in female genital</span></p>
<p style="top:213.6pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">tract tumors or breast neoplasms with no further restrictions.</span></p>
<p style="top:236.8pt;left:76.5pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">4.2. Search Strategy</span></i></p>
<p style="top:256.3pt;left:97.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">We performed electronic database searches in EMBASE (DataStar Version, Cary, NC, USA) and</span></p>
<p style="top:269.8pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">MEDLINE (Ovid version, New York, NY, USA). The search was conducted using the following</span></p>
<p style="top:283.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Emtree</span><span style="font-family:Rpxr,serif;font-size:10.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">MeSH terms: &#x201c;ibrutinib&#x201d; or &#x201c;PCI32765&#x201d; in combination with &#x201c;female genital tract tumor&#x201d;</span></p>
<p style="top:296.9pt;left:76.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">(Emtree) or &#x201c;genital neoplasms, female&#x201d; (MeSH), and &#x201c;breast tumor&#x201d; (Emtree) or &#x201c;breast neoplasms&#x201d;</span></p>
<p style="top:310.3pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">(MeSH). The Emtree</span><span style="font-family:Rpxr,serif;font-size:10.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Mesh terms were expanded in order to include narrower terms (e.g., &#x201c;ovary</span></p>
<p style="top:323.9pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">tumor&#x201d; or &#x201c;breast cancer&#x201d;). Boolean operators were used as conjunctions to extend or limit the search,</span></p>
<p style="top:337.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">as described in Tables</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt;color:#0774b7"> A1</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> and</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt;color:#0774b7"> A2</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">. All matching publications were screened. The manual exclusion was</span></p>
<p style="top:351.0pt;left:76.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">performed after screening the titles and</span><span style="font-family:Rpxr,serif;font-size:9.9pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">or abstracts to identify eligible publications. The bibliographies</span></p>
<p style="top:364.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">of all articles that ful&#xfb01;lled the inclusion criteria were reviewed to identify other articles that ful&#xfb01;lled</span></p>
<p style="top:377.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">the inclusion criteria.</span></p>
<p style="top:391.4pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Clinical trials were searched in</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt;color:#0774b7"> Clinicaltrials.gov</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> (United States Library of Medicine, Bethesda,</span></p>
<p style="top:405.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">MD, USA) using the following terms in the respective search &#xfb01;elds condition or disease: &#x201c;solid tumor&#x201d;,</span></p>
<p style="top:418.5pt;left:75.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">&#x201c;gynecologic cancer&#x201d;, &#x201c;ovarian cancer&#x201d;, &#x201c;fallopian tube cancer&#x201d;, &#x201c;peritoneal cancer&#x201d;, &#x201c;cervical cancer&#x201d;,</span></p>
<p style="top:431.9pt;left:75.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">&#x201c;uterine cancer&#x201d;, &#x201c;corpus uteri cancer&#x201d;, &#x201c;corpus uteri carcinoma&#x201d;, &#x201c;endometrial cancer&#x201d;, &#x201c;vaginal</span></p>
<p style="top:445.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">cancer&#x201d;, &#x201c;vulvar cancer&#x201d;, &#x201c;breast cancer&#x201d;; other terms (medication): &#x201c;ibrutinib&#x201d;.</span></p>
<p style="top:468.7pt;left:76.5pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">4.3. Data Collection Process, Data Items</span></i></p>
<p style="top:488.1pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Due to inevitable methodological inconsistencies in the studies retrieved and experiments</span></p>
<p style="top:501.6pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">conducted, standardized data extraction could not be performed.</span></p>
<p style="top:501.6pt;left:404.4pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Findings were extracted</span></p>
<p style="top:515.2pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">independently in a narrative way to the best of our ability.</span></p>
<p style="top:538.1pt;left:76.2pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Author Contributions:</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Conceptualization, J.M.M. and D.F..; methodology, J.M.M. and L.B.; formal analysis,</span></p>
<p style="top:548.3pt;left:76.4pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">J.M.M. and L.B.; investigation, J.M.M.; data curation, J.M.M. and L.B.; writing&#x2014;original draft preparation, J.M.M.;</span></p>
<p style="top:558.3pt;left:76.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">writing&#x2014;review and editing, all authors; visualization, J.M.M.; validation, P.I.; supervision, P.I. and D.F.; project</span></p>
<p style="top:568.5pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">administration, J.M.M. All authors have read and agreed to the published version of the manuscript.</span></p>
<p style="top:584.6pt;left:76.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Funding:</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> This research received no external funding.</span></p>
<p style="top:600.7pt;left:76.2pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Acknowledgments:</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Thanks to Carla Trachsel for proofreading the article.</span></p>
<p style="top:616.8pt;left:76.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Con&#xfb02;icts of Interest:</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> The authors declare no con&#xfb02;ict of interest.</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 4154</span></p>
<p style="top:56.6pt;left:491.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">13 of 17</span></p>
<p style="top:89.9pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Abbreviations</span></b></p>
<p style="top:109.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">BMX</span></p>
<p style="top:109.7pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Bone marrow X-linked kinase</span></p>
<p style="top:122.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">BTK</span></p>
<p style="top:122.1pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Bruton&#x2019;s tyrosine kinase</span></p>
<p style="top:134.5pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">cGVHD</span></p>
<p style="top:134.5pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Chronic graft versus host disease</span></p>
<p style="top:146.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">CLL</span></p>
<p style="top:146.8pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Chronic lymphocytic leukemia</span></p>
<p style="top:159.2pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">CSC</span></p>
<p style="top:159.2pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Cancer stem cell</span></p>
<p style="top:171.6pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">CTL</span></p>
<p style="top:171.6pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Cytotoxic T lymphocytes</span></p>
<p style="top:184.0pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">DC</span></p>
<p style="top:184.0pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Dendritic cell</span></p>
<p style="top:196.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">EGFR</span></p>
<p style="top:196.4pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Epidermal growth factor receptor</span></p>
<p style="top:208.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ER</span></p>
<p style="top:208.8pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Estrogene receptor</span></p>
<p style="top:221.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">i.v.</span></p>
<p style="top:221.1pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Intravenously</span></p>
<p style="top:233.5pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">IC50</span></p>
<p style="top:233.5pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Half-maximal inhibitory concentration</span></p>
<p style="top:245.9pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">IFN</span></p>
<p style="top:245.9pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Interferon</span></p>
<p style="top:258.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">IL</span></p>
<p style="top:258.3pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Interleukin</span></p>
<p style="top:270.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ITK</span></p>
<p style="top:270.7pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">interleukin-2-inducible T-cell kinase</span></p>
<p style="top:283.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">MDSC</span></p>
<p style="top:283.1pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Myeloid-derived suppressor cell</span></p>
<p style="top:295.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">MeSH</span></p>
<p style="top:295.4pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Medical Subject Headings</span></p>
<p style="top:307.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">MZL</span></p>
<p style="top:307.8pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Marginal zone lymphoma</span></p>
<p style="top:320.2pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">NCI</span></p>
<p style="top:320.2pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">National cancer institute</span></p>
<p style="top:332.6pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">NSCLC</span></p>
<p style="top:332.6pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Non-small-cell lung cancer</span></p>
<p style="top:345.0pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ORR</span></p>
<p style="top:345.0pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Overall response rate</span></p>
<p style="top:357.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">PARP</span></p>
<p style="top:357.4pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">poly-ADP-ribose-polymerase</span></p>
<p style="top:369.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">PD-1</span></p>
<p style="top:369.8pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Programmed cell death protein 1</span></p>
<p style="top:382.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">PD-L1</span></p>
<p style="top:382.1pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Programmed death-ligand 1</span></p>
<p style="top:394.5pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">PR</span></p>
<p style="top:394.5pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Progesterone receptor</span></p>
<p style="top:406.9pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">q2w</span></p>
<p style="top:406.9pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2-weekly, every 2 weeks</span></p>
<p style="top:419.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">RLK</span></p>
<p style="top:419.3pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Redundant-resting lymphocyte kinase</span></p>
<p style="top:431.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">SLL</span></p>
<p style="top:431.7pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Small lymphocytic lymphoma</span></p>
<p style="top:444.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">TEC</span></p>
<p style="top:444.1pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Tec protein tyrosine kinase</span></p>
<p style="top:456.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">TFK</span></p>
<p style="top:456.4pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">TEC family kinase</span></p>
<p style="top:468.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">TNBC</span></p>
<p style="top:468.8pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Triple-negative breast cancer</span></p>
<p style="top:481.2pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">WM</span></p>
<p style="top:481.2pt;left:141.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Waldenstrom&#x2019;s macroglobulinemia</span></p>
<p style="top:505.0pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Appendix A</span></b></p>
<p style="top:537.0pt;left:146.3pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Table A1.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Search outcomes in Medline. A search performed on 1 April 2020.</span></p>
<p style="top:557.3pt;left:122.8pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Number</span></b></p>
<p style="top:557.3pt;left:261.4pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Search Terms</span></b></p>
<p style="top:557.3pt;left:408.5pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Search Items Medline</span></b></p>
<p style="top:569.9pt;left:134.7pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">1</span></p>
<p style="top:569.9pt;left:257.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">ibrutinib (Mesh)</span></p>
<p style="top:569.9pt;left:425.8pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">2026 results</span></p>
<p style="top:583.1pt;left:134.7pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">2</span></p>
<p style="top:578.7pt;left:190.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">(&#x2018;genital neoplasms, female&#x2019; [Mesh]) OR &#x2018;breast neoplasms&#x2019;</span></p>
<p style="top:587.4pt;left:272.1pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">[Mesh]</span></p>
<p style="top:583.1pt;left:421.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">498.349 results</span></p>
<p style="top:596.2pt;left:134.7pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">3</span></p>
<p style="top:596.2pt;left:269.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">1 AND 2</span></p>
<p style="top:596.2pt;left:431.2pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">4 results</span></p>
<p style="top:621.3pt;left:147.3pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Table A2.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Search outcomes in Embase. A search performed on 1 April 2020.</span></p>
<p style="top:641.6pt;left:122.8pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Number</span></b></p>
<p style="top:641.6pt;left:261.4pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Search Terms</span></b></p>
<p style="top:641.6pt;left:409.7pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Search Items Embase</span></b></p>
<p style="top:654.2pt;left:134.7pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">1</span></p>
<p style="top:654.2pt;left:254.7pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">ibrutinib (Emtree)</span></p>
<p style="top:654.2pt;left:425.8pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">6186 results</span></p>
<p style="top:663.0pt;left:134.7pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">2</span></p>
<p style="top:663.0pt;left:197.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">&#x2018;female genital tract tumor&#x2019;</span><span style="font-family:Rpxr,serif;font-size:7.2pt">/</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">exp OR &#x2018;breast tumor</span><span style="font-family:Rpxr,serif;font-size:7.2pt">/</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">exp&#x2019;</span></p>
<p style="top:663.0pt;left:421.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">866.090 results</span></p>
<p style="top:671.7pt;left:134.7pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">3</span></p>
<p style="top:671.7pt;left:269.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">1 AND 2</span></p>
<p style="top:671.7pt;left:429.4pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">84 results</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 4154</span></p>
<p style="top:56.6pt;left:491.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">14 of 17</span></p>
<p style="top:559.7pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:5.4pt;left:148.7pt;line-height:9.0pt"><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:9.0pt">Table A2. </span></b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Search outcomes in Embase.</span><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:9.0pt"> </span></b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">A search performed on 1 April 2020. </span></p>
<p style="top:24.5pt;left:120.6pt;line-height:9.0pt"><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:9.0pt">Number </span></b></p>
<p style="top:24.5pt;left:245.0pt;line-height:9.0pt"><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:9.0pt">Search Terms </span></b></p>
<p style="top:24.5pt;left:390.8pt;line-height:9.0pt"><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:9.0pt">Search Items Embase </span></b></p>
<p style="top:37.1pt;left:135.6pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">1 </span></p>
<p style="top:37.1pt;left:237.0pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">ibrutinib (Emtree) </span></p>
<p style="top:37.1pt;left:410.8pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">6186 results </span></p>
<p style="top:49.2pt;left:135.6pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">2 </span></p>
<p style="top:49.2pt;left:165.9pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">&apos;female genital tract tumor&apos;/exp OR &apos;breast tumor/exp&apos; </span></p>
<p style="top:49.2pt;left:405.3pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">866.090 results </span></p>
<p style="top:61.4pt;left:135.6pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">3 </span></p>
<p style="top:61.4pt;left:255.5pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">1 AND 2 </span></p>
<p style="top:61.4pt;left:415.3pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">84 results </span></p>
<p style="top:251.6pt;left:431.2pt;line-height:12.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:12.0pt"> </span></p>
<p style="top:272.7pt;left:216.7pt;line-height:9.0pt"><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:9.0pt">Figure A1. </span></b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Search results of clinical trials. </span></p>
<p style="top:297.1pt;left:78.1pt;line-height:10.0pt"><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:10.0pt">References </span></b></p>
<p style="top:323.2pt;left:78.1pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">1.</span><span style="font-family:Arial,sans-serif;font-size:9.0pt"> </span></p>
<p style="top:323.2pt;left:95.9pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Dubovsky, J.A.; Beckwith, K.A.; Natarajan, G.; Woyach, J.A.; Jaglowski, S.; Zhong, Y.; Hessler, J.D.; Liu, T.-</span></p>
<p style="top:336.2pt;left:95.9pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">M.; Chang, B.Y.; Larkin, K.M.; et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-</span></p>
<p style="top:349.2pt;left:95.9pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">selective pressure in T lymphocytes. </span><i><span style="font-family:PalatinoLinotype,Italic,serif;font-size:9.0pt">Blood</span></i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt"> </span><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:9.0pt">2013</span></b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">, </span><i><span style="font-family:PalatinoLinotype,Italic,serif;font-size:9.0pt">122</span></i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">, 2539&#x2013;2549, doi:10.1182/blood-2013-06-507947. </span></p>
<p style="top:362.2pt;left:78.0pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">2.</span><span style="font-family:Arial,sans-serif;font-size:9.0pt"> </span></p>
<p style="top:362.2pt;left:95.9pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Chen, J.; Kinoshita, T.; Sukbuntherng, J.; Chang, B.Y.; Elias, L. Ibrutinib Inhibits ERBB Receptor Tyrosine </span></p>
<p style="top:375.2pt;left:95.9pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Kinases and HER2-Amplified Breast Cancer Cell Growth. </span><i><span style="font-family:PalatinoLinotype,Italic,serif;font-size:9.0pt">Mol. Cancer Ther.</span></i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt"> </span><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:9.0pt">2016</span></b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">, </span><i><span style="font-family:PalatinoLinotype,Italic,serif;font-size:9.0pt">15</span></i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">, 2835&#x2013;2844, </span></p>
<p style="top:388.2pt;left:95.9pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">doi:10.1158/1535-7163.MCT-15-0923. </span></p>
<p style="top:401.2pt;left:78.0pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">3.</span><span style="font-family:Arial,sans-serif;font-size:9.0pt"> </span></p>
<p style="top:401.2pt;left:95.9pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Campbell, R.; Chong, G.; Hawkes, E. Novel Indications for Bruton&#x2019;s Tyrosine Kinase Inhibitors, beyond </span></p>
<p style="top:414.2pt;left:95.9pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Hematological Malignancies. </span><i><span style="font-family:PalatinoLinotype,Italic,serif;font-size:9.0pt">J. Clin. Med.</span></i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt"> </span><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:9.0pt">2018</span></b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">, </span><i><span style="font-family:PalatinoLinotype,Italic,serif;font-size:9.0pt">7</span></i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">, 62, doi:10.3390/jcm7040062. </span></p>
<p style="top:427.2pt;left:78.0pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">4.</span><span style="font-family:Arial,sans-serif;font-size:9.0pt"> </span></p>
<p style="top:427.2pt;left:95.9pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Molina-Cerrillo, J.; Alonso-Gordoa, T.; Gajate, P.; Grande, E. Bruton&#x2019;s tyrosine kinase (BTK) as a promising </span></p>
<p style="top:440.2pt;left:95.9pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">target in solid tumors. </span><i><span style="font-family:PalatinoLinotype,Italic,serif;font-size:9.0pt">Cancer Treat. Rev.</span></i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt"> </span><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:9.0pt">2017</span></b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">, </span><i><span style="font-family:PalatinoLinotype,Italic,serif;font-size:9.0pt">58</span></i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">, 41&#x2013;50, doi:10.1016/j.ctrv.2017.06.001. </span></p>
<p style="top:453.2pt;left:78.0pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">5.</span><span style="font-family:Arial,sans-serif;font-size:9.0pt"> </span></p>
<p style="top:453.2pt;left:95.9pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Pharmacyclics Inc. Imbruvica&#xae; (ibrutinib) [package insert]. U.S. Food and Drug Administration website. </span></p>
<p style="top:466.2pt;left:95.9pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Available </span></p>
<p style="top:466.2pt;left:148.0pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">online: </span></p>
<p style="top:466.2pt;left:188.9pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">www.accessdata.fda.gov/drugsatfda_docs/label/2019/205552s029,210563s004lbl.pdf </span></p>
<p style="top:479.2pt;left:95.9pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">(revised July 2019, accessed on January 1, 2020)</span><i><span style="font-family:PalatinoLinotype,Italic,serif;font-size:9.0pt">.</span></i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt"> </span></p>
<p style="top:492.2pt;left:78.0pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">6.</span><span style="font-family:Arial,sans-serif;font-size:9.0pt"> </span></p>
<p style="top:492.2pt;left:95.9pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Wei, L.; Su, Y.-K.; Lin, C.-M.; Chao, T.-Y.; Huang, S.-P.; Huynh, T.-T.; Jan, H.-J.; Whang-Peng, J.; Chiou, J.-</span></p>
<p style="top:505.2pt;left:95.9pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">F.; Wu, A.T.; et al. Preclinical investigation of ibrutinib, a Bruton&#x2019;s kinase tyrosine (Btk) inhibitor, in </span></p>
<p style="top:518.2pt;left:95.9pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">suppressing glioma tumorigenesis and stem cell phenotypes. </span><i><span style="font-family:PalatinoLinotype,Italic,serif;font-size:9.0pt">Oncotarget</span></i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt"> </span><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:9.0pt">2016</span></b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">, </span><i><span style="font-family:PalatinoLinotype,Italic,serif;font-size:9.0pt">7</span></i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">, 69961&#x2013;69975, </span></p>
<p style="top:531.2pt;left:95.9pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">doi:10.18632/oncotarget.11572. </span></p>
<p style="top:544.2pt;left:78.0pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">7.</span><span style="font-family:Arial,sans-serif;font-size:9.0pt"> </span></p>
<p style="top:544.2pt;left:95.9pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Gao, W.; Wang, M.; Wang, L.; Lu, H.; Wu, S.; Dai, B.; Ou, Z.; Zhang, L.; Heymach, J.V.; Gold, K.A.; et al. </span></p>
<img style="position:absolute;transform:matrix(.5634616,0,-0,.563293,86.66803,25.975998)" src="data:image/png;base64,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">
<p style="top:267.5pt;left:215.2pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Figure A1.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Search results of clinical trials.</span></p>
<p style="top:290.9pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">References</span></b></p>
<p style="top:310.6pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">1.</span></p>
<p style="top:310.7pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Dubovsky, J.A.; Beckwith, K.A.; Natarajan, G.; Woyach, J.A.; Jaglowski, S.; Zhong, Y.; Hessler, J.D.; Liu, T.-M.;</span></p>
<p style="top:323.6pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Chang, B.Y.; Larkin, K.M.; et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective</span></p>
<p style="top:336.4pt;left:97.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">pressure in T lymphocytes.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Blood</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2013</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 122</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 2539&#x2013;2549. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:349.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2.</span></p>
<p style="top:349.2pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Chen, J.; Kinoshita, T.; Sukbuntherng, J.; Chang, B.Y.; Elias, L. Ibrutinib Inhibits ERBB Receptor Tyrosine</span></p>
<p style="top:362.3pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Kinases and HER2-Ampli&#xfb01;ed Breast Cancer Cell Growth.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Mol. Cancer Ther.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 15</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 2835&#x2013;2844. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>
<p style="top:375.1pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:388.0pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">3.</span></p>
<p style="top:388.0pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Campbell, R.; Chong, G.; Hawkes, E. Novel Indications for Bruton&#x2019;s Tyrosine Kinase Inhibitors, beyond</span></p>
<p style="top:401.0pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Hematological Malignancies.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Clin. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 7</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 62. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:413.9pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">4.</span></p>
<p style="top:413.9pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Molina-Cerrillo, J.; Alonso-Gordoa, T.; Gajate, P.; Grande, E. Bruton&#x2019;s tyrosine kinase (BTK) as a promising</span></p>
<p style="top:426.8pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">target in solid tumors.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cancer Treat. Rev.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 58</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 41&#x2013;50. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:439.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">5.</span></p>
<p style="top:439.6pt;left:98.0pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Pharmacyclics Inc.</span></p>
<p style="top:439.6pt;left:187.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Imbruvica</span><span style="font-family:Rpcxr,serif;font-size:9.0pt">&#xae;</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt">(ibrutinib) [package insert].</span></p>
<p style="top:439.6pt;left:363.3pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">U.S. Food and Drug Administration</span></p>
<p style="top:452.7pt;left:97.6pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Website. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7"> www.accessdata.fda.gov</span><span style="font-family:Rpxr,serif;font-size:8.9pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">drugsatfda_docs</span><span style="font-family:Rpxr,serif;font-size:8.9pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">label</span><span style="font-family:Rpxr,serif;font-size:8.9pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">2019</span><span style="font-family:Rpxr,serif;font-size:8.9pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">205552s029,210563s004lbl.pdf</span></p>
<p style="top:465.5pt;left:97.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">(accessed on 1 January 2020).</span></p>
<p style="top:478.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">6.</span></p>
<p style="top:478.4pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Wei, L.; Su, Y.-K.; Lin, C.-M.; Chao, T.-Y.; Huang, S.-P.; Huynh, T.-T.; Jan, H.-J.; Whang-Peng, J.; Chiou, J.-F.;</span></p>
<p style="top:491.4pt;left:97.6pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Wu, A.T.; et al. Preclinical investigation of ibrutinib, a Bruton&#x2019;s kinase tyrosine (Btk) inhibitor, in suppressing</span></p>
<p style="top:504.3pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">glioma tumorigenesis and stem cell phenotypes.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 7</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 69961&#x2013;69975. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:517.2pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">7.</span></p>
<p style="top:517.1pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Gao, W.; Wang, M.; Wang, L.; Lu, H.; Wu, S.; Dai, B.; Ou, Z.; Zhang, L.; Heymach, J.V.; Gold, K.A.; et al.</span></p>
<p style="top:530.0pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non&#x2013;Small Cell Lung Cancer Cells.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> J. Natl.</span></i></p>
<p style="top:543.0pt;left:97.8pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Cancer Inst.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2014</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 106</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:555.9pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">8.</span></p>
<p style="top:555.8pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Mass</span><span style="font-family:VnURWPalladioL,serif;font-size:9.0pt">&#xf3;</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt">-Vall</span><span style="font-family:VnURWPalladioL,serif;font-size:9.0pt">&#xe9;</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt">s, D.; Jauset, T.; Soucek, L. Ibrutinib repurposing: From B-cell malignancies to solid tumors.</span></p>
<p style="top:568.8pt;left:97.7pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Oncoscience</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 3</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 147&#x2013;148. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:581.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">9.</span></p>
<p style="top:581.7pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Bond, D.A.; Woyach, J.A. Targeting BTK in CLL: Beyond Ibrutinib.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Curr. Hematol. Malign. Rep.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 14</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span></p>
<p style="top:594.6pt;left:97.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">197&#x2013;205. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:607.5pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">10.</span></p>
<p style="top:607.5pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Atkinson, B.T.; Ellmeier, W.; Watson, S.P. Tec regulates platelet activation by GPVI in the absence of Btk.</span></p>
<p style="top:620.5pt;left:97.8pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Blood</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2003</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 102</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 3592&#x2013;3599. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:633.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">11.</span></p>
<p style="top:633.3pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Quek, L.; Bolen, J.; Watson, S.P. A role for Bruton&#x2019;s tyrosine kinase (Btk) in platelet activation by collagen.</span></p>
<p style="top:646.3pt;left:97.8pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Curr. Biol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 1998</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 8</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1137&#x2013;1140. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:659.2pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">12.</span></p>
<p style="top:659.2pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Younes, A.; Thieblemont, C.; Morschhauser, F.; Flinn, I.W.; Friedberg, J.W.; Amorim, S.; Hivert, B.; Westin, J.;</span></p>
<p style="top:672.0pt;left:97.7pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Vermeulen, J.; Bandyopadhyay, N.; et al. Combination of ibrutinib with rituximab, cyclophosphamide,</span></p>
<p style="top:685.0pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell</span></p>
<p style="top:698.0pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">non-Hodgkin lymphoma: A non-randomised, phase 1b study.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Lancet Oncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2014</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 15</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 1019&#x2013;1026. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>
<p style="top:710.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">13.</span></p>
<p style="top:710.9pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Jaglowski, S.M.; Jones, J.A.; Nagar, V.; Flynn, J.M.; Andritsos, L.A.; Maddocks, K.J.; Woyach, J.A.; Blum, K.A.;</span></p>
<p style="top:723.8pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Grever, M.R.; Smucker, K.; et al. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab</span></p>
<p style="top:736.7pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">in chronic lymphocytic leukemia: A phase 1b</span><span style="font-family:Rpxr,serif;font-size:9.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2 study.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Blood</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 126</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 842&#x2013;850. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 4154</span></p>
<p style="top:56.6pt;left:491.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">15 of 17</span></p>
<p style="top:90.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">14.</span></p>
<p style="top:90.6pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Chanan-Khan, A.; Cramer, P.; Demirkan, F.; Fraser, G.; Silva, R.S.; Grosicki, S.; Pristupa, A.; Janssens, A.;</span></p>
<p style="top:103.7pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Mayer, J.; Bartlett, N.L.; et al. Ibrutinib combined with bendamustine and rituximab compared with placebo,</span></p>
<p style="top:116.5pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic</span></p>
<p style="top:129.5pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">lymphoma (HELIOS): A randomised, double-blind, phase 3 study.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Lancet Oncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 17</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 200&#x2013;211. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>
<p style="top:142.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">15.</span></p>
<p style="top:142.3pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">A Multi-Center Study of Ibrutinib in Combination with MEDI4736 in Subjects With Relapsed or Refractory</span></p>
<p style="top:155.2pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Solid Tumors. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7"> https:</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">//</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">ClinicalTrials.gov</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">show</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">NCT02403271</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 30 April 2020).</span></p>
<p style="top:168.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">16.</span></p>
<p style="top:168.1pt;left:98.0pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt;color:#0774b7"> https:</span></p>
<p style="top:181.1pt;left:97.5pt;line-height:9.0pt"><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">//</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">ClinicalTrials.gov</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">show</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">NCT03379428</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 30 April 2020).</span></p>
<p style="top:194.0pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">17.</span></p>
<p style="top:193.9pt;left:98.0pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Ibrutinib and Nivolumab in Treating Participants with Metastatic Solid Tumors. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt;color:#0774b7"> https:</span></p>
<p style="top:206.9pt;left:97.5pt;line-height:9.0pt"><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">//</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">ClinicalTrials.gov</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">show</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">NCT03525925</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 30 April 2020).</span></p>
<p style="top:219.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">18.</span></p>
<p style="top:219.8pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Wu, J.; Liu, C.; Tsui, S.T.; Liu, D. Second-generation inhibitors of Bruton tyrosine kinase.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Hematol. Oncol.</span></i></p>
<p style="top:232.7pt;left:98.1pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 9</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 80. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:245.6pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">19.</span></p>
<p style="top:245.5pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">AstraZeneca. Calquence</span><span style="font-family:Rpcxr,serif;font-size:9.0pt">&#xae;</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt">(acalabrutinib) [package insert]. U.S. Food and Drug Administration website.</span></p>
<p style="top:258.5pt;left:97.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Available online:</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7"> www.accessdata.fda.gov</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">drugsatfda_docs</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">label</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">2019</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">210259s006s007lbl.pdf</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on</span></p>
<p style="top:271.4pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">27 May 2020).</span></p>
<p style="top:284.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">20.</span></p>
<p style="top:284.3pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Wu, J.; Zhang, M.; Liu, D. Acalabrutinib (ACP-196):</span></p>
<p style="top:284.3pt;left:331.2pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">A selective second-generation BTK inhibitor.</span></p>
<p style="top:297.3pt;left:98.1pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">J. Hematol. Oncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 9</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 21. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:310.2pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">21.</span></p>
<p style="top:310.1pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Barf, T.; Covey, T.; Izumi, R.; Van De Kar, B.; Gulrajani, M.; Van Lith, B.; Van Hoek, M.; De Zwart, E.;</span></p>
<p style="top:323.1pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Mittag, D.; Demont, D.; et al. Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a</span></p>
<p style="top:336.0pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Di</span><span style="font-family:Rpxr,serif;font-size:8.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">erentiated Selectivity and In Vivo Potency Pro&#xfb01;le.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> J. Pharmacol. Exp. Ther.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 363</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 240&#x2013;252. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>
<p style="top:348.9pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:361.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">22.</span></p>
<p style="top:361.9pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">BeiGene. Brukinsa</span><span style="font-family:Rpcxr,serif;font-size:9.0pt">&#xae;</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">(zanubrutinib) [package insert]. U.S. Food and Drug Administration website. Available</span></p>
<p style="top:374.7pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">online:</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7"> www.accessdata.fda.gov</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">drugsatfda_docs</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">label</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">2019</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">213217s000lbl.pdf</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 27 May 2020).</span></p>
<p style="top:387.6pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">23.</span></p>
<p style="top:387.7pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Liclican, A.; Sera&#xfb01;ni, L.; Xing, W.; Czerwieniec, G.; Steiner, B.; Wang, T.; Brendza, K.M.; Lutz, J.D.; Keegan, K.S.;</span></p>
<p style="top:400.5pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Ray, A.S.; et al. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton&#x2019;s</span></p>
<p style="top:413.4pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">tyrosine kinase reveals di</span><span style="font-family:Rpxr,serif;font-size:9.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">erences in on&#x2014;and o</span><span style="font-family:Rpxr,serif;font-size:9.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">&#x2014;arget inhibition.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Biochim. Biophys. Acta BBA Gen. Subj.</span></i></p>
<p style="top:426.4pt;left:98.1pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 1864</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 129531. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:439.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">24.</span></p>
<p style="top:439.2pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Caldwell, R.D.; Qiu, H.; Askew, B.C.; Bender, A.T.; Brugger, N.; Camps, M.; Dhanabal, M.; Dutt, V.;</span></p>
<p style="top:452.3pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Eichhorn, T.; Gardberg, A.S.; et al. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent</span></p>
<p style="top:465.1pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Bruton&#x2019;s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Med. Chem.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span></p>
<p style="top:478.0pt;left:98.1pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">62</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 7643&#x2013;7655. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:490.9pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">25.</span></p>
<p style="top:490.9pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Study of Evobrutinib in Participants with Relapsing Multiple Sclerosis (RMS). Available online:</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt;color:#0774b7"> https:</span></p>
<p style="top:503.8pt;left:97.5pt;line-height:9.0pt"><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">//</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">ClinicalTrials.gov</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">show</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">NCT04032158</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 27 May 2020).</span></p>
<p style="top:516.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">26.</span></p>
<p style="top:516.8pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Armstrong, D.K.; Alvarez, R.D.; Bakkum-Gamez, J.N.; Barroilhet, L.; Behbakht, K.; Berchuck, A.; Berek, J.S.;</span></p>
<p style="top:529.6pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Chen, L.-M.; Cristea, M.; DeRosa, M.; et al. NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.</span></p>
<p style="top:542.6pt;left:98.1pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">J. Natl. Compr. Cancer Netw.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 17</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 896&#x2013;909. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:555.5pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">27.</span></p>
<p style="top:555.4pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Bottoni, P.; Scatena, R. The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Adv. Exp.</span></i></p>
<p style="top:568.4pt;left:98.1pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Med. Biol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 867</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 229&#x2013;244. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:581.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">28.</span></p>
<p style="top:581.4pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Ledermann, J.A.; Pujade-Lauraine, E. Olaparib as maintenance treatment for patients with platinum-sensitive</span></p>
<p style="top:594.2pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">relapsed ovarian cancer.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Ther. Adv. Med. Oncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 11</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1758835919849753. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:607.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">29.</span></p>
<p style="top:607.1pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Colombo, N.; Sessa, C.; Du Bois, A.; Ledermann, J.; McCluggage, W.G.; McNeish, I.; Morice, P.; Pignata, S.;</span></p>
<p style="top:620.1pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Ray-Coquard, I.; Vergote, I.; et al. ESMO&#x2013;ESGO consensus conference recommendations on ovarian cancer:</span></p>
<p style="top:632.9pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.</span></p>
<p style="top:645.9pt;left:97.7pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Ann. Oncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 30</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 672&#x2013;705. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:658.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">30.</span></p>
<p style="top:658.7pt;left:98.0pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">National Comprehensive Cancer Network. Ovarian Cancer (Version 1.2020). Available online:</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt;color:#0774b7"> https:</span><span style="font-family:Rpxr,serif;font-size:9.1pt;color:#0774b7">//</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt;color:#0774b7">www.</span></p>
<p style="top:671.7pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">nccn.org</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">professionals</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">physician_gls</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">pdf</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">ovarian.pdf</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 29 March 2020).</span></p>
<p style="top:684.6pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">31.</span></p>
<p style="top:684.5pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2019.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> CA Cancer J. Clin.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 69</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">, 7&#x2013;34. [</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt">]</span></p>
<p style="top:697.5pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:710.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">32.</span></p>
<p style="top:710.5pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Waks, A.G.; Winer, E.P. Breast Cancer Treatment: A Review.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> JAMA</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 321</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 288&#x2013;300. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>
<p style="top:723.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">33.</span></p>
<p style="top:723.3pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Grabinski, N.; Ewald, F. Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell</span></p>
<p style="top:736.3pt;left:97.8pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">viability of ErbB2-positive breast cancer cells.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Investig. New Drugs</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2014</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 32</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 1096&#x2013;1104. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 4154</span></p>
<p style="top:56.6pt;left:491.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">16 of 17</span></p>
<p style="top:90.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">34.</span></p>
<p style="top:90.6pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Sagiv-Bar&#xfb01;, I.; Kohrt, H.E.K.; Czerwinski, D.K.; Ng, P.P.; Chang, B.Y.; Levy, R. Therapeutic antitumor</span></p>
<p style="top:103.5pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Proc. Natl.</span></i></p>
<p style="top:116.5pt;left:97.7pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Acad. Sci. USA</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 112</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, E966&#x2013;E972. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:129.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">35.</span></p>
<p style="top:129.5pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Sti</span><span style="font-family:Rpxr,serif;font-size:8.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, A.; Trikha, P.; Wesolowski, R.; Kendra, K.; Hsu, V.; Uppati, S.; McMichael, E.L.; Duggan, M.; Campbell, A.;</span></p>
<p style="top:142.4pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Keller, K.; et al. Myeloid-Derived Suppressor Cells Express Bruton&#x2019;s Tyrosine Kinase and Can Be Depleted in</span></p>
<p style="top:155.2pt;left:97.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Tumor-Bearing Hosts by Ibrutinib Treatment.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cancer Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 76</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 2125&#x2013;2136. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:168.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">36.</span></p>
<p style="top:168.1pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Eifert, C.; Wang, X.; Kokabee, L.; Kourtidis, A.; Jain, R.; Gerdes, M.J.; Conklin, D.S. A novel isoform of the</span></p>
<p style="top:181.0pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">B cell tyrosine kinase BTK protects breast cancer cells from apoptosis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Genes Chromosom. Cancer</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2013</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 52</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span></p>
<p style="top:194.0pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">961&#x2013;975. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:206.9pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">37.</span></p>
<p style="top:206.8pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Wang, X.; Wong, J.; Sevinsky, C.J.; Kokabee, L.; Khan, F.; Sun, Y.; Conklin, D.S. Bruton&#x2019;s Tyrosine Kinase</span></p>
<p style="top:219.7pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Mol. Cancer Ther.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 15</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">, 2198&#x2013;2208.</span></p>
<p style="top:232.7pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:245.6pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">38.</span></p>
<p style="top:245.5pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Di, J.; Zheng, B.; Kong, Q.; Jiang, Y.; Liu, S.; Yang, Y.; Han, X.; Sheng, Y.; Zhang, Y.; Cheng, L.; et al.</span></p>
<p style="top:258.5pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by</span></p>
<p style="top:271.4pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">integrating pathway activities and drug activities.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Mol. Oncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 2259&#x2013;2277. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:284.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">39.</span></p>
<p style="top:284.3pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Hong, D.S.; Rasco, D.; Veeder, M.; Luke, J.J.; Chandler, J.; Balmanoukian, A.; George, T.J.; Munster, P.;</span></p>
<p style="top:297.2pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Berlin, J.D.; Gutierrez, M.; et al. A Phase 1b</span><span style="font-family:Rpxr,serif;font-size:9.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and</span></p>
<p style="top:310.1pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Oncology</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 97</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">, 102&#x2013;111.</span></p>
<p style="top:323.1pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:336.0pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">40.</span></p>
<p style="top:335.9pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Varikuti, S.; Singh, B.; Volpedo, G.; Ahirwar, D.K.; Jha, B.K.; Saljoughian, N.; Viana, A.G.; Verma, C.;</span></p>
<p style="top:348.8pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Hamza, O.; Halsey, G.; et al. Ibrutinib treatment inhibits breast cancer progression and metastasis by</span></p>
<p style="top:361.9pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">inducing conversion of myeloid-derived suppressor cells to dendritic cells.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Br. J. Cancer</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 122</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 1005&#x2013;1013.</span></p>
<p style="top:374.7pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:387.6pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">41.</span></p>
<p style="top:387.7pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Le Naour, A.; Ko</span><span style="font-family:Rpxr,serif;font-size:9.0pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, Y.; Diab, M.; Le Guennec, D.; Roug</span><span style="font-family:VnURWPalladioL,serif;font-size:9.0pt">&#xe9;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, S.; Aldekwer, S.; Goncalves-Mendes, N.; Talvas, J.;</span></p>
<p style="top:400.6pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Farges, M.; Calde&#xfb01;e-Chezet, F.; et al. The EO771 mammary cancer cell line displays a luminal B phenotype</span></p>
<p style="top:413.5pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">and it is sensitive to anti-estrogen treatments.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Biorxiv</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:426.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">42.</span></p>
<p style="top:426.4pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Zucha, M.A.; Wu, A.T.; Lee, W.H.; Wang, L.S.; Lin, W.W.; Yuan, C.C.; Yeh, C.T. Bruton&#x2019;s tyrosine kinase (Btk)</span></p>
<p style="top:439.3pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">inhibitor ibrutinib suppresses stem-like traits in ovarian cancer.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 6</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 13255&#x2013;13268. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>
<p style="top:452.2pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:465.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">43.</span></p>
<p style="top:465.0pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Tamura, H.; Higa, A.; Hoshi, H.; Hiyama, G.; Takahashi, N.; Ryufuku, M.; Morisawa, G.; Yanagisawa, Y.;</span></p>
<p style="top:478.1pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Ito, E.; Imai, J.I.; et al. Evaluation of anticancer agents using patient-derived tumor organoids characteristically</span></p>
<p style="top:490.9pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">similar to source tissues.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Oncol. Rep.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 40</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 635&#x2013;646. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:503.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">44.</span></p>
<p style="top:503.8pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Lohse, I.; Azzam, D.J.; Al-Ali, H.; Volmar, C.H.; Brothers, S.P.; Ince, T.A.; Wahlestedt, C. Ovarian Cancer</span></p>
<p style="top:516.7pt;left:97.8pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Treatment Strati&#xfb01;cation Using Ex Vivo Drug Sensitivity Testing.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Anticancer Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 39</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">, 4023&#x2013;4030.</span></p>
<p style="top:529.7pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:542.6pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">45.</span></p>
<p style="top:542.7pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Berglof, A.; Hamasy, A.; Meinke, S.; Palma, M.; Krsti&#xb4;c, A.; M&#xe5;nsson, R.; Kimby, E.; &#xd6;sterborg, A.; Smith, C.I.E.</span></p>
<p style="top:555.6pt;left:97.8pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Targets for Ibrutinib Beyond B Cell Malignancies.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Scand. J. Immunol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 82</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 208&#x2013;217. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>
<p style="top:568.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">46.</span></p>
<p style="top:568.3pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Uitdehaag, J.C.M.; Kooijman, J.J.; De Roos, J.A.M.; Prinsen, M.B.W.; Dylus, J.; Willemsen-Seegers, N.;</span></p>
<p style="top:581.4pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Kawase, Y.; Sawa, M.; De Man, J.; Van Gerwen, S.J.C.; et al. Combined Cellular and Biochemical Pro&#xfb01;ling to</span></p>
<p style="top:594.2pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between</span></p>
<p style="top:607.1pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2013 and 2017.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Mol. Cancer Ther.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 18</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 470&#x2013;481. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:620.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">47.</span></p>
<p style="top:620.1pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Li, K.; Pan, W.-T.; Ma, Y.-B.; Xu, X.-L.; Gao, Y.; He, Y.-Q.; Wei, L.; Zhang, J.-W. BMX activates Wnt</span><span style="font-family:Rpxr,serif;font-size:9.0pt">/</span><span style="font-family:EURM10,serif;font-size:9.0pt">&#x3b2;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">-catenin</span></p>
<p style="top:632.9pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">signaling pathway to promote cell proliferation and migration in breast cancer.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Breast Cancer</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 27</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span></p>
<p style="top:645.9pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">363&#x2013;371. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:658.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">48.</span></p>
<p style="top:658.8pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Li, Y.; Cui, N.; Zheng, P.-S.; Yang, W.-T. BMX</span><span style="font-family:Rpxr,serif;font-size:9.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Etk promotes cell proliferation and tumorigenicity of cervical</span></p>
<p style="top:671.6pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">cancer cells through PI3K</span><span style="font-family:Rpxr,serif;font-size:9.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">AKT</span><span style="font-family:Rpxr,serif;font-size:9.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">mTOR and STAT3 pathways.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 8</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 49238&#x2013;49252. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:684.6pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:697.5pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">49.</span></p>
<p style="top:697.5pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Fox, J.L.; Storey, A. BMX Negatively Regulates BAK Function, Thereby Increasing Apoptotic Resistance to</span></p>
<p style="top:710.4pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Chemotherapeutic Drugs.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cancer Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 75</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1345&#x2013;1355. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 4154</span></p>
<p style="top:56.6pt;left:491.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">17 of 17</span></p>
<p style="top:90.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">50.</span></p>
<p style="top:90.7pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Horna, P.; Sotomayor, E.M. Cellular and molecular mechanisms of tumor-induced T-cell tolerance.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Curr. Cancer</span></i></p>
<p style="top:103.6pt;left:97.7pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Drug Targets</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2007</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 7</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 41&#x2013;53. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:116.5pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">51.</span></p>
<p style="top:116.5pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Loose, D.; Van De Wiele, C. The Immune System and Cancer.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cancer Biother. Radiopharm.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2009</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 24</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 369&#x2013;376.</span></p>
<p style="top:129.4pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<img style="position:absolute;transform:matrix(.221696,0,-0,.221696,-91.16266,133.995)" src="data:image/png;base64,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">
<p style="top:150.4pt;left:167.8pt;line-height:9.0pt"><span style="font-family:Rpcxr,serif;font-size:9.0pt">&#xa9;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access</span></p>
<p style="top:163.3pt;left:169.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">article distributed under the terms and conditions of the Creative Commons Attribution</span></p>
<p style="top:176.3pt;left:169.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">(CC BY) license (http:</span><span style="font-family:Rpxr,serif;font-size:9.0pt">//</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">creativecommons.org</span><span style="font-family:Rpxr,serif;font-size:9.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">licenses</span><span style="font-family:Rpxr,serif;font-size:9.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">by</span><span style="font-family:Rpxr,serif;font-size:9.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">4.0</span><span style="font-family:Rpxr,serif;font-size:9.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">).</span></p>

</div>
